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                                                            ABSTRACT 
 




XIAN WU,  
B.S., CHINA PHARMACEUTICAL UNIVERSITY, NANJING, CHINA 
Ph.D., UNIVERSITY OF MASSACHUSETTS, AMHERST, MA 
 
Directed by: Professor Hang Xiao 
 
Colon cancer is one of the major global public health issues, which severely 
threatens human health. Polymethoxyflavones (PMFs), a unique class of flavonoids, are 
abundantly and almost exclusively found in the peel of sweet oranges (Citrus sinensis) 
and mandarin oranges (Citrus reticulata). Nobiletin (NBT) is a major citrus flavonoid 
that has shown various health benefits, including anti-inflammation and anti-
carcinogenesis. To better understand the chemopreventive effects of NBT, we 
systematically investigated the inhibitory effects of dietary NBT on colitis-associated 
colon carcinogenesis in azoxymethane (AOM)/dextran sulfate sodium (DSS)-treated 
mice. We found that oral administration of NBT effectively decreased both incidence and 
multiplicity of colonic tumors. NBT showed significant anti-proliferative, pro-apoptotic 
and anti-inflammatory effects in the mouse colon. HPLC analysis revealed that oral 
administration of NBT resulted in high levels of metabolites in the colonic mucosa. In 
contrast, the colonic level of NBT was about 20-fold lower than the total colonic level of 
three metabolites.  Cell culture studies demonstrated that the colonic metabolites of NBT 
significantly inhibited the growth of human colon cancer cells, caused cell cycle arrest, 
induced apoptosis, and profoundly modulated signaling proteins related with cell 
proliferation and cell death. All of these effects were much stronger than those produced 
by NBT alone.  
4'-Demethylnobiletin (4DN) is a major metabolite of NBT, and its tissue level 
was found to be much higher than that of NBT after oral administration of NBT in mice. 
Our results showed that 4DN effectively inhibited lipopolysaccharide (LPS)-induced 
inflammatory responses in RAW 264.7 cells macrophage cells, such as production of 
!
vii!
NO, PGE2, and gene expression of iNOS and COX-2 via modulating NF-κB, AP-1 and 
Nrf2 pathways. Moreover, 4DN suppressed 12-O-tetradecanoylphorbol-13-acetate 
(TPA)-stimulated skin inflammation in mice, and its effect was much stronger than that 
produced by NBT. The anti-inflammatory effects by 4DN were associated with 
suppression of TPA-stimulated production of IL-1β, IL-6 and TNF-α, and reduction of 
protein expression of iNOS, COX-2 and MMP-9. Furthermore, the results indicated that 
4DN was able to up-regulate the expression levels of phase II anti-oxidative enzymes 
HO-1 and NQO1 in TPA-treated mouse ears.  
Accumulating studies suggests that cancer chemopreventive agents in 
combination may act synergistically and produce enhanced protective effects against 
carcinogenesis than each individual agent. Next we investigated the synergistic 
anticancer effects of NBT and atorvastatin (ATST, a lipid-lowering drug) in combination 
in human colon cancer cells and an AOM-induced colon carcinogenesis rat model. Co- 
treatments of NBT/ATST at half doses produced much stronger inhibitory effects on 
colon cancer cells compared to those produced by NBT or ATST alone at full doses. 
Isobologram analysis confirmed these two compounds have strong synergistic 
interaction. Animal study showed that oral intake of NBT/ATST in combination 
produced synergistic inhibitory effect on tumor incidence and multiplicity in comparison 
to those produced by individual NBT or ATST. Our results also indicated that co-
treatment of NBT/ATST had much stronger anti-proliferative, pro-apoptotic and anti-
inflammatory effects in AOM-treated rats than that produced by NBT or ATST alone.  
In conclusion, these studies provided a scientific basis for using NBT as a 
nutraceutical for colon cancer chemoprevention, as well as using NBT and ATST in 
combination for enhanced cancer protective efficacy.   
!
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cancer related signaling proteins in the colonic mucosa of AOM-
treated rats. Colon tissues samples were randomly collected from the 
middle and distal colon, and then subjected to Western Blot analysis. 
The numbers underneath of the blots represent band intensity 
(normalized to β-actin, means of three independent experiments) 
measured by Image J software. The SDs (all within ±15% of the 
means) were not shown. β-Actin was served as an equal loading 
control. * indicates statistical significance in comparison with the 
control (p < 0.05, n=3). (B) Effects of NBT, ATST, and their half dose 
combination treatments on membrane-bound proteins in the colonic 
mucosa of AOM-treated rats. Membrane-bound proteins were 
prepared as described in Material  and methods. The numbers 
underneath of the blots represent band intensity (normalized to β-actin, 
means of three independent experiments) measured by Image J 
software. The SDs (all within ±15% of the means) were not shown. β-
tubulin was served as an equal loading control. * indicates statistical 







Colon cancer is defined as any malignant tumor arising from the inner wall of the 
colonic epithelium. Colon cancer remains a leading cause of caner death in US and 
worldwide. Colon cancer occurrence is mainly associated with the formation of aberrant 
crypt foci (ACF), an early stage neoplastic lesion. ACF are clusters of colonic mucosal 
cells with inflamed and thicker layer of epithelial cells than their surrounding normal 
crypts. ACF can further progress and develop into colorectal polys, adenomas and 
adenocarcinomas sequentially, as consequences of the accumulation of genetic alterations 
in colonic epithelia(1). Although the overall mortality rate of colon cancer has fallen 
significantly over the past decades, it is estimated that 93,090 people in USA will be 
diagnosed with colon cancer and 49,700 deaths will be attributed to this disease in 
2015(2). Epidemiological studies have shown that the occurrence of colon cancer is 
closely related with inherited cancer predisposition syndromes, as well as some other risk 
factors, such as obesity, smoking, alcohol consumption, high fat diet, inadequate intake 
of vegetables, fruits and dietary fiber, and lack of physical exercise(1, 3, 4). Although 
various risk factors may affect the lifetime risk of developing colon cancer, the average 
of that is about 5.1%. Once the uncontrollable cells form to tumor, patients have to be 
treated with unwanted surgery, chemotherapy or other targeted therapies. Complications 
and serious side effects are associated with their long-term use. As of this date, a cure 
remains elusive and pharmaceutical drugs have been limited in their capability to alter the 
disease process(1). Fortunately, cancer is preventable. A large amount of researches 
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showed that reduced alcohol and tobacco intake, weight reduction, daily physical 
exercise and health diet could help to reduce lifetime cancer risk(5).  
Colon cancer can be prevented to some extent by consuming natural products 
with chemopreventive properties, such as herbs, fruits, and vegetables. Chemoprevention 
is defined as an approach of utilizing!dietary bioactive components and/or their synthetic 
analogs for intervention to inhibit, delay, reverse or retard the process of 
carcinogenesis(6). Epidemiological studies have suggested that higher vegetables and 
fruits consumption may help reduce the risk of colon cancer. The chemopreventive 
effects of natural products can be attributed to the bioactive components!present in these 
foods(1, 7).  More than 25,000 different phytochemicals have been reported to have 
potential protective effects against multiple cancers(8). Using phytochemicals have 
various advantages, because very few unwanted side effects has been reported during 
animal and human studies, and they usually target multiple signaling pathways(1, 8).  
Polymethoxyflavones (PMFs) is a unique group of flavonoid that bears two or more 
methoxyl groups on their basic benzo'γ'pyrone skeleton with a carbonyl group at the C4 
position. Nobiletin (5,6,7,8,3',4'-hexamethoxyflavone, NBT) is a major citrus PMF 
presented in orange peel extract(9). Previous studies have demonstrated a wide range of 
biologically beneficial activities of NBT, including anti-inflammation(10, 11), 
antitumor(12-16), and anti-atherosclerosis(17).!Recently, hydroxylated PMFs, mainly 5-
hydroxylated PMFs, have gained increasing attention due to their superior anti-
carcinogenic effects than those produced by their counterparts(18, 19).   
Biotransformation plays principal roles in the biological activities of orally 
ingested bioactive components(20, 21). The metabolites generated in the body after oral 
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ingestion may have different bioactivities. The metabolites generated in the body after 
oral ingestion may have different bioactivities. On the other hand, in certain organ or 
tissue, metabolites achieve higher concentrations than their parent compound. Therefore, 
the metabolites, rather than the ingested components, may exhibit dominant biological 
effects in that organ or tissue. Therefore, the molecular mechanisms that involved in the 
anti-carcinogenic effects of the colonic metabolites of PMFs may be closely associated 
with their application. 
Combination treatments of two or more chemopreventive agents that have distinct 
molecular targets may produce enhanced bioactivities than those produced by each single 
agent alone. These synergistic interactions among chemopreventive agents can result in 
stronger protective effects against cancer. Moreover, combination regimens can also 
lower the required dose for individual agent in the combination, and in turn reduce and 
minimize unwanted side effects caused by long-term and high dose administration of 
individual chemopreventive agent. There is a growing body of studies suggesting the 
potential health benefits of combining pharmaceutical drugs with dietary bioactive 
components to prevent and treat cancer(22). 
Our long-term goal is to develop diet-based strategies that are safe and cost-
efficient alternative approaches for colon cancer chemoprevention. To reach that goal, the 
overall objective of this project is to develop effective colon cancer chemoprevention 
strategies utilizing PMFs. Our central hypothesis is PMFs and their metabolites are able 
to exhibit anti-inflammatory and anticancer activities against colon carcinogenesis. 
Moreover, PMFs will exert synergistic chemopreventive effects in combination with 
atorvastatin (ATST) on colon carcinogenesis. Our hypothesis has been cultivated on the 
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results of preliminary data regarding the anti-inflammatory and anticancer efficacy of 
PMFs, and enhanced growth inhibitory effects of PMFs and ATST in combination on 
lung cancer cells. 
We will test our central hypothesis and achieve our objective by utilizing the 
following four specific aims: 
1. Determine the chemopreventive effects of nobiletin (NBT) and its colonic 
metabolites on colon carcinogenesis. An azoxymethane (AOM)/ dextran 
sulfate sodium (DSS)-induced colitis-associated colon carcinogenesis mice 
model will be used to assess the antitumor efficacy of NBT in vivo. 
Histological evaluation will be performed to assess the colon adenocarcinoma 
formation and other parameters in AOM/DSS–treated mice. Colonic mucosa 
will be subjected to immunohistochemical analysis, ELISA and qRT-PCR 
analysis to determine the mechanism of action of NBT on colon carcinogenesis. 
Colonic mucosa samples will then be subjected to HPLC to determine the 
levels of NBT and its metabolites. The in vitro anticancer effects of NBT and 
its metabolites on human colon cancer cells will be evaluated using cell 
viability assay. Flow cytometry analysis and western blot will be utilized to 
determine the effects of NBT and its metabolites on cell cycle arrest and 
apoptosis.  
 
2. Determine the in vitro and in vivo anti-inflammatory efficacy of 4'-
demethylnobiletin (4DN), a major metabolite of nobiletin. The in vitro anti-
inflammatory efficacy of 4DN will be determined in lipopolysaccharide (LPS)-
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stimulated RAW 264.7 macrophages. Nitric oxide assay and ELISA will be 
performed to determine the effects of 4DN against pro-inflammatory response. 
Western blotting analysis and qRT-PCR analysis will be utilized to evaluate the 
expression levels of key pro-inflammatory proteins. The in vivo anti-
inflammatory effects of 4DN will be determiend by using a 12-O-
tetradecanoylphorbol-13-acetate (TPA)-induced skin inflammation mouse 
model. Ear tissues will be subjected to ELISA and western blotting analysis to 
study the underlying molecular mechanisms. 
 
3. Determine the!potential synergistic chemopreventive effects of nobiletin 
(NBT) and atorvastatin (ATST) in combination on colon carcinogenesis. The 
in vitro growth inhibitory effects of NBT, ATST, and their combinations on 
human colon cancer cells will be determined using cell viability assay. 
Isobologram analysis will be constructed to verify if the enhanced growth 
inhibitory effects are synergistic or not. Flow cytometry analysis will be 
utilized to determine the effects of NBT, ATST and the co-treatments on cell 
cycle arrest and apoptosis. We expect to observe the synergistic inhibition by 
NBT and ATST on human colon cancer cells. AOM will be injected to rats to 
induce colon carcinogenesis in vivo. Histological evaluation will be performed 
to assess the colon adenocarcinoma formation and other parameters in AOM–
treated rats. Colonic mucosa will be subjected to qRT-PCR and western blot 







2.1.1 Overview of colorectal cancer 
At present, colorectal cancer is one of the most common malignancies in both 
men and women not only in US, bot also worldwide. Although the overall mortality rate 
of colorectal cancer has fallen significantly over the past decades, it is estimated that 
93,090 people in USA will be diagnosed with colon cancer and 49,700 deaths will be 
attributed to this disease in 2015(2). Epidemiological studies have shown that the 
occurrence of colorectal cancer is closely related with inherited cancer predisposition 
syndromes, as well as some other risk factors, such as obesity, smoking, environmental 
procarcinogens, alcohol consumption, high fat diet, inadequate intake of vegetables, fruits 
and dietary fiber, and lack of physical exercise(1, 3, 4). In addition, colorectal cancer is 
strongly associated with inflammatory bowel diseases (IBD), such as ulcerative colitis 
and Crohn’s disease. Epidemiological evidences indicated that around 40% colitis 
patients developed into colorectal cancer later in life(23). Inflammation promotes 
carcinogenesis by various mechanisms including enhancing proliferation of malignant 
cells, promoting angiogenesis, boosting tumor metastasis, and altering tumor response to 
chemotherapeutic drugs (24). Particularly in colorectal cancer, inflammatory cells that 
produce pro-inflammatory cytokines and various reactive oxygen species can generate 
significant oxidative stress in colonic tissues. Numerous studies have shown that 
oxidative stress could affect multiple carcinogenic signaling pathways through enhanced 
malignant in DNA, RNA, proteins and lipids. On the other hand, inflammatory 
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microenvironment in colonic tissues can further facilitate the carcinogenesis process. 
Cytokines and chemokines secreted by inflammatory cells also have immunosuppressive 
effects that can promote tumor growth(25). Colon carcinogenesis over a long period of 
time as various genetic and epigenetic changes in chronic inflammation, cell proliferation, 
cell survival, differentiation, apoptosis, angiogenesis and tumor metastasis.  
 
!
2.1.2 Introduction to chemoprevention 
Previous researches have suggested that about 30-40% of cancer incidents could 
be prevented by daily exercise, low fat and healthy diet, reduction of body weight, 
avoidance of tobacco, and reduced alcohol intake. In terms of low fat and healthy diet, 
high consumption of fruits and vegetables is linked to around 20% lower risk of cancer 
occurrence. Chemoprevention was first established by Sporn in the 1970’s, and is defined 
as an approach of utilizing!dietary bioactive components and/or their synthetic analogs 
for intervention to inhibit, delay, reverse or retard the process of carcinogenesis(6). The 
phytochemicals presented in fruits, vegetables and herbs have gained increasing attention 
in chemoprevention research. 
Currently, toxicities with the high dose usage of anticancer medicines continue to 
be a subject of great concern. Therefore, chemoprevention by natural products and their 
constitutes is a promising strategy for cancer prevention and treatment, due to its nature 
of cost-effective, low toxicity, less unwanted side effects, and easy availability. 
Chemopreventive agents will not only benefit healthy individuals, but also individuals 
with high risk of cancer occurrence and cancer patients. Studies have suggested that 




2.1.3 Molecular targets and signaling pathways for chemoprevention 
Epidemiological studies and molecular studies have shown that inflammatory 
conditions increase the risk of malignancy. Chronic inflammation has tumor-promoting 
effects by various mechanisms including enhancing proliferation of malignant cells, 
promoting tumor angiogenesis and metastasis, and altering tumor response to 
chemotherapeutic drugs (24). In tumor cells and inflammatory cells, eukaryotic 
transcription factor nuclear factor-kappa B (NF-κB) contributes to the activation of genes 
coding pro-inflammatory enzymes, such as induce inducible nitric oxide synthase (iNOS) 
and cyclooxygenase-2 (COX-2), which in turn stimulates the expression of nitric oxide 
(NO) and prostaglandins, respectively. Prostaglandin E2 (PGE2), the major bioactive lipid 
derived from COX-2 activity, is a key inflammatory mediator that promote tumor growth 
and metastasis. Similarly, iNOS-mediated overproduction of NO can cause modifications 
and structure damage of DNA, and promote tumor angiogenesis (26). NF-κB also triggers 
the expression of pro-inflammatory cytokines, such as interleukin-1β (IL-1β). Besides 
NF-κB, activator protein 1 (AP-1) is another transcription factor that plays an important 
role in the regulation of the expression of genes responsible for inflammatory responses 
including iNOS and COX-2 (27). Nuclear factor erythroid 2-related factor 2 (Nrf2), a 
redox-sensitive transcription factor, translocates to the nucleus and triggers the 
expression of a set of phase II detoxification and antioxidant enzymes including heme 
oxygenase-1 (HO-1) and NADH quinone oxidoreductase 1 (NQO1) when stimulated by 
pro-oxidant stimulus. In contrast to the pro-inflammatory effects of NF-κB and AP-1, 
Nrf2 was reported to inhibit abnormal inflammatory response (28), and alleviate adverse 
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effects of LPS-induced NF-κB activation (29). Previous studies have shown that 
increased HO-1 and NQO1 expression contributed to the adaptive increase of cellular 
anti-oxidant and anti-carcinogenic capacity (30). Since Nrf2 and its downstream anti-
oxidative enzymes play critical roles in down-regulation of inflammation, they are 
important targets for anti-inflammation remedy. 
Key signaling pathways related to apoptosis and cell proliferation are often 
deregulated during the promotion stage of carcinogenesis. Apoptosis is a form of 
programmed cell death that plays an essential role in development and tissue homeostasis. 
During apoptosis process, the morphology of cells changes, chromatin condensate, DNA 
fragmentizes, and finally lead to cell death. In contrast to necrosis, apoptosis process is 
highly regulated by a set of cellular components. There are two major apoptotic pathways, 
extrinsic and intrinsic pathway. The evasion of apoptosis is one of the most common 
cellular abnormalities that may facilitate the development of various cancers (31). 
Proteolytic cleavage of procaspases is a critical step in caspase activation, which can in 
turn alter other downstream molecular targets. Activation (cleavage) of caspase-9 and its 
downstream effector caspase-3 play critical roles in triggering cellular apoptosis. 
Cleavage of caspase-3 can lead to the activation (cleavage) of other key proteins, such as 
PARP, which can ultimately promote apoptosis by interfering chromatin condensation 
and DNA fragmentation(32). The loss of regulated cell cycle and normal cell behavior is 
one of the important hallmarks of cancer. Cell cycle is tightly controlled by checkpoints, 
and different cyclin-CDK (cyclin-dependent kinase) complexes. p21Cip1/Waf1 is a key 
regulator of cell cycle that can inhibit CDK activities and thus control the cell cycle 
progression at G1 and S phase. The transition of cell cycle from G1 to S phase is mainly 
!
10!
regulated by cyclin D-CDK4/6 complexes. Induction of p21Cip1/Waf1 can in turn cause the 
inactivation or degradation of cyclin D1, leading to cell cycle arrest in G0/G1 stage (33). 
Therefore, chemopreventive agents that induce cellular apoptosis and cell cycle 
progression might be useful in inhibiting cancerous cell proliferation.  
Progression stage of carcinogenesis involves unlimited replication of tumor cells, 
activation of angiogenesis (new blood vessel formation), beginning of tissue invasion and 
metastasis growth. During angiogenesis process, new blood vessels are formed from 
endothelial cells that allows tumors to obtain nutrient and oxygen supply and in turn start 
to invade their surrounding tissues. Vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF) are two major growth factors that are recruited and further 
activate endothelial cell functions. VEGF and FGF are often found to be highly expressed 
in many tumors. Migration and invasion of tumor cells are important events during 
metastasis process of carcinogenesis. When solid tumors obtain adequate nutrient supply 
from new blood vessels, they will start to expand from the primary tumor mass into 
surrounding tissues. In addition, tumor cells are able to travel through blood stream and 
migrate to secondary tissues. Proteolysis enzymes matrix metalloproteinases (MMPs) 
plays important roles in the disruption of extracellular matrix. Among MMP family, 
MMP-2 and MMP-9 are two main proteolysis enzymes that break down extracellular 
matrix structure and thus open paths for tumor cells migration. MMP-2 and MMP-9 have 
been identified in various cancers. Therefore, angiogenesis and metastasis process are 





2.1.4 The role of dietary components in cancer prevention and therapy 
Epidemiological studies have suggested that higher vegetables and fruits 
consumption may help reduce the risk of colon cancer. The chemopreventive effects of 
natural products can be attributed to the bioactive components!present in these foods(1, 
7).  More than 25,000 different phytochemicals have been reported to have potential 
protective effects against various cancers(8). Using phytochemicals have various 
advantages, because very few unwanted side effects has been reported during animal and 
human studies, and they usually target multiple signaling pathways(1, 8). Dietary 
phytochemicals have been demonstrate to modulate more than one deregulated signaling 
pathways related to carcinogenesis, including inflammation, DNA repair, cellular 
apoptosis, cell cycle progression, angiogenesis, metastasis, migration, and carcinogen 
metabolism. In animal models, natural products and the bioactive components isolated 
from them have been shown to exhibit protective activities against multiple cancers. 
Fruits, vegetables, and herbs and their isolated constituents that process chemopreventive 
effects include resveratrol from grape, lycopene from tomato, β-carotene from carrot, 
lutein from spinach and kale, epigallocatechin-3-gallate (EGCG) from tea, 
proanthocyanidins from cranberry, genistein from soybean, 6-gingerol from ginger, and 
sulforaphane from broccoli. They can be categorized into several classes. We will discuss 
available information on the chemopreventive properties of some representative 
phytochemicals. 
Lycopene is an abundant carotenoid found in tomato, carrot, papaya, watermelon 
and some grapefruits that provides a bright red color. The majority of dietary lycopene is 
from tomato species. A large number of studies have revealed the protective effects of 
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lycopene against prostate cancer!in the past decades(25). A lower risk of prostate cancer 
has been associated with the higher consumption of tomato products. This can be 
attributed to its strong antioxidant activity that protects γ-radiation-induced DNA damage 
and lipid peroxidation(34). It also has been suggested to inhibit the smoke-induced lung 
tumorigenesis and azoxymethane (AOM)-induced colon carcinogenesis in animal 
models(25).  
Green tea catechins have been extensively studied due to their potent health-
promoting effects in recent years. Tea is one of the most popular beverages all over the 
world. There are three major types of tea: non-fermented green tea, semi-fermented 
oolong tea and fermented black tea. Accumulating epidemiological studies have shown 
that the high consumption of tea help reduce the risk of cancer. The polyphenolic 
compounds found in tea are mainly responsible for these chemopreventive effects. The 
most abundant polyphenolic compounds presented in tea are catechins. Among different 
catechins, such as epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), 
epicatechin-3-gallate (ECG), and epicatechin (EC), EGCG has been of particular 
attention as it is the major catechin found in green tea(25). Numerous in vitro and in vivo 
studies have indicated the cancer preventive effects of EGCG against lung, breast, 
prostate, colon, and stomach cancers. EGCG exert the chemopreventive effects by 
modulating multiple signaling pathways, including induction of apoptosis and cell cycle 
arrest of cancerous cells, inhibition of NF-κB, AP-1, MAPKs pathways. EGCG is able to 
suppress the epidermal growth factor receptor (EGFR) and Insulin-like growth factor 
(IGF)-I mediated pathways, as well as interfere the angiogenesis, metastasis, and 
migration process during cancer development(35).  
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Sulforaphane is an aliphatic isothiocyanates mainly obtained from cruciferous 
plants, such as broccoli and cabbages. It is a known anti-inflammatory and anti-cancer 
agent. Sulforaphane has been shown to inhibit the phosphorylation of Akt, JNK and ERK, 
and gene expression of iNOS and COX-2. Furthermore, sulforaphane is able to modulate 
Nrf2 pathway, thus induce the gene expression of a set of phase II detoxification and 
antioxidant enzymes including HO-1 and NQO1. The anti-inflammatory efficacy of 
sulforaphane may contribute to its anti-carcinogenic effects.  
!
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2.2 Polymethoxyflavones and their metabolites 
2.2.1 Introduction to polymethoxyflavones 
Due to the unique flavors and nutritional values, citrus fruits, such as oranges, 
tangerines, lemons, limes and grapefruits, are widely consumed and have become an 
important part of our diet. According to the National Agricultural Statistics Service, 
current annual citrus production in the United States was 17,800,000 boxes in 2013-2014, 
with Florida constituting 65% as the leading state, followed by California, Texas and 
Arizona. Around a third of citrus fruit was used for juice production; in turn generated 
approximately 4-5 billion lbs. wasted peels as by-products every year(9). Citrus peels are 
processed to obtain the volatile and nonvolatile fractions in food, pharmaceutical and 
cosmetic industry. In some Asian countries, aged citrus peels have been utilized as 
traditional medicinal resources since ancient times to treat various diseases, such as 
abdominal fullness and distention, cough, stomach upset, skin inflammation, and 
hypertension. Fresh citrus fruits are good sources of dietary fibers and carbohydrates. In 
addition to these macronutrients, citrus fruits contain significant amount of vitamins and 
phytochemicals, including flavonoids, carotenoids, and limonoids. Due to the antioxidant 
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activities of these constituents, they are of great importance in the health beneficial 
effects of citrus fruits(36).  
Polymethoxyflavones (PMFs) are unique flavonoids almost exclusively found in 
citrus plants (sweet oranges and mandarin oranges) that bear two or more methoxyl 
groups on their basic benzo-γ-pyrone skeleton (15-carbon, C6-C3- C6) with a carbonyl 
group at the C4 position(9). There have been more than 20 PMFs being isolated and 
identified from citrus fruits, such as sinensetin (5,6,7,3′,4′-pentamethoxy-flavone), 
nobiletin (5,6,7,8,3′,4′-hexamethoxyflavone, NBT), tangeretin (5,6,7,8,4′-
pentamethoxyflavone, TAN), and 3,5,6,7,8,3′,4′-heptamethoxyflavone. PMFs are the 
secondary compounds located in the peel (especially in the flavedo) that act as antifungal 
agents (protection against pathogenic!fungi attack)(37). These secondary compounds are 
presented in the highest levels in the peels of young fruits. However, it has been 
suggested that the formation of some PMFs, such as 5-hydroxy-6,7,8,3′,4′-
pentamethoxyflavone (5-demethylnobiletin, 5DN), 5-hydroxy-3,6,7,8,3′,4′- 
hexamethoxyflavone (5DH), and 5-hydroxy-6,7,8,4′-tetramethoxyflavone (5-
demethyltangeretin, 5DT) was related to the auto-hydrolysis during long-term storage, 
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Figure 2.1 Chemical structures of polymethoxyflavones (PMFs). (A) Nobiletin (NBT) 
and (B) tangeretin (TAN) are major permethoxylated PMFs found in the peels of sweet 
oranges. During aging process, (C) 5-demethylnobiletin (5DN) and (D) 5-





2.2.2 Biotransformation of polymethoxyflavones 
A growing body of evidence suggested that biotransformation played critical roles 
in the biological activities of orally administered compounds (20, 21). The metabolites 
generated in the body by the biotransformation may have more potent bioactivities in 
comparison with the parent compound (39, 40). Moreover, oral administration of a parent 
compound may result in higher levels of metabolites than the parent compound in certain 
tissues. Therefore, under the aforementioned circumstance, the metabolites, rather than 
the ingested parent compound, may exhibit dominant biological effects in those tissues 
(40). In recent years, the biological properties of PMFs have been extensively reported, 
however, knowledge of the biotransformation profile of PMFs is still limited. Previous 
studies suggested that the primary sites of biotransformation of PMFs are 3′ and 4′ 
positions on the B-ring, and therefore the number and position of the hydroxyl and 
methoxyl groups on the B-ring significantly affect the metabolism and biological 
activities of PMFs(41-46). We will discuss available information of the biotransformation 
of some major PMFs. 
 
2.2.2.1 Nobiletin 
We and others have reported that nobiletin (5,6,7,8,3′,4′-hexamethoxyflavone, 
NBT) undergo extensive biotransformation to produce various metabolites(41-45). 
Murakami et al. first reported the in vitro absorption and metabolism of NBT by utilizing 
a rat liver S9 mixture. Treatment of NBT with S9 mixture for 24 h resulted in the 
formation of 3'-demethylnobiletin (M1, as shown in Figure 2.3B)(41). Koga et al. studied 
the in vitro metabolism of NBT using liver microsomes of rats, hamsters,!guinea pigs and 
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ten rat cytochrome P450. As shown in Figure 2.2, five metabolites of NBT were 
identified after incubation with liver microsomes. Constitutive P450s CYP2C11, 
CYP2C12, CYP2D1, CYP3A1 and CYP3A2 were found to be responsible for 
demethylation at the 6-, 7-, 3′- and 4′-positions in rings A and B, whereas inducible 
P450s CYP1A1 and CYP1A2 catalyzed demethylation at the 3′- and 4′-positions in ring 
B(43).!Yasuda et al. reported that oral adiministration of NBT to rats led to the formation 
of 4'-demethylnobiletin (M2, as shown in Figure 2.3C) with two other minor metabolites 
in the urine(42). Li et al. further investigated the metabolites of NBT in mouse urine. The 
results showed that NBT underwent mono-demethylation and di-demethylation pathways, 
and therefore produced 3 major demethylated metablited 3'-demethylnobiletin (M1), 4'-









Recently, we identified and quantified major metabolites of NBT in the colonic 
mucosa, namely 3'-demethylnobiletin (M1), 4'-demethylnobiletin (M2), and 3', 4'-
didemethylnobiletin (M3). Moreover, the abundance of these metabolites were about 20-
fold higher than that of their parent compound NBT in the colonic mucosa. It is likely 
that their formation is the result of phase I & II metabolism as well as biotransformation 
by gut microbiome, as shown in Figure 2.3(47). These findings suggested that due to its 
high abundance, metabolites of NBT might play important roles in the biological effects 















Figure 2.3 Chemical structures of (A) NBT and its metabolites (B) 3'-demethylnobiletin 
(M1), (C) 4'-demethylnobiletin (M2), and (D) 3', 4'-didemethylnobiletin (M3). (E)!




In vitro metabolism of tangeretin (5,6,7,8,4′-pentamethoxyflavone, TAN) was 
studied by using human and murine cytochrome P450s. As shown in Figure 2.4, the 
major metabolites were identified as 4′,7-dihydroxy-5,6,8-trimethoxyflavone, 4′,6-
dihydroxy-5,7,8-trimethoxyflavone, 3′,4′-dihydroxy-5,6,7,8-tetramehoxyflavone,!4′-
hydroxy-5,6,7,8-tetramethoxyflavone, and 5,6-dihydroxy-4′,7,8-trimethoxyflavone(48).  
Whereas the in vivo biotransformation study of TAN indicated that the major 
metabolites presented in rat urine and feces were 4′-hydroxy-5,6,7,8-
tertramethoxyflavone, 3′,4′-dihydroxy-5,6,7,8-tetramehoxyflavone, and 4′,6-dihydroxy-
5,7,8-trimethoxyflavone, with six other minor metabolites. Hence, these results suggested 
that 4′ position on the B-ring of TAN was the primary site for demethylation, and 3′ 
position on the B-ring was most active site for hydroxylation. In addition, 38% of TAN 




Figure 2.4 Biotransformation pathways of TAN (Adapted from Nielsen et al., 2000 and 





Among different types of PMFs, 5-hydroxylated PMFs are a unique subclass(9). 
Although the relative abundance of 5-hydroxylated PMFs is relatively less than that of 
their permethoxylated counterparts. Our previous studies have demonstrated that 5-
demethylnobiletin (5DN) and 5-demethyltangeretin (5DT), two of important 5-
hydroxylated PMFs, exhibited superior anticancer potential than their counterparts 
against multiple types of cancers(18, 19).  
The in vivo biotransformation study of 5DN by gavage feeding on mice for 24 h 
identified three major phase I metabolites from HPLC-ESI-MS analysis, namely!5,3′-
didemethylnobiletin, 5,4′ -didemethylnobiletin, and 5,3′4′-tridemethylnobiletin, as shown 
in Figure 2.5. Among these three metabolites, 5,4′-didemethylnobiletin was the most 
abundant, while 5,3′-didemethylnobiletin and 5,3′4′-tridemethylnobiletin were much less 
abundant. Similarly to NBT and TAN, 4′ position on the B-ring of 5DN was also the 
primary site for demethylation. In addition, significant amount of 5DN and its 
metabolites were in their conjugated forms as!glucuronides and/or sulfates after phase II 












2.2.3 Bioactivities of polymethoxyflavones and their metabolites 
PMFs have been gained growing attentions due to their wide range of beneficial 
activities that help ameliorate human health, including anti-inflammation (10, 11, 50), 
anti-carcinogenesis (12-16, 18, 46), anti-obesity(51) and anti-atherosclerosis (17). 
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2.2.3.1 Anti-inflammatory benefits  
Numerous findings have indicated that PMFs exhibited their anti-inflammatory 
effects via the inhibition of inflammatory enzymes, such as inducible nitric oxide 
synthase (iNOS), cyclooxygenase-2 (COX-2) and NADPH oxidase that generate 
inflammatory mediators like NO, prostaglandin E2 (PGE2) and superoxide anion(10, 52).  
NBT is a major PMF and has been reported to have with a wide range of 
biological activities, including anti-inflammation (45, 53). In vitro studies showed that 
NBT inhibited LPS-induced production of NO and PGE2 in RAW 264.7 macrophages 
(53), and suppressed gene expression of pro-inflammatory cytokines including IL-1β, IL-
6 and TNF-α in J774A.1 macrophages (54). In vivo studies demonstrated that NBT 
inhibited TPA-induced skin inflammation (10) and suppressed dextran sulfate sodium-
induced colitis (15). More importantly, after oral administration, NBT was transformed to 
its demethylated metabolites such as 3'-demethylnobiletin (M1), 4'-demethylnobiletin 
(M2), and 3', 4'-didemethylnobiletin (M3). The abundance of these metabolites were 
about much higher than that of their parent compound NBT in certain tissues. Li et al. 
reported that NBT metabolites, especially M2 and M3, had much stronger anti-
inflammatory effects than NBT in LPS-stimulated RAW 264.7 macrophages(45).! 
TAN has been shown to suppress LPS-induced inflammatory response by 
attenuating gene expression of pro-inflammatory enzymes iNOS and COX-2 and pro-
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inflammatory cytokines IL-1α, IL-1β, IL-6 and TNF-α, and blocking the activation of 
transcription factors activator protein 1 (AP-1)(55) and nuclear factor-kappa B (NF-
κB)(56). In vivo biotransformation study of TAN indicated that the major metabolites 
presented in rat urine and feces were 4′-hydroxy-5,6,7,8-tertramethoxyflavone (4DT)(49). 
Our previous study compared the anti-inflammatory activities of TAN and 4DT in LPS-
treated macrophages, and found that 4DT had superior effects than TAN in lowering the 
production of NO and PGE2 and decreasing the activation of p38, JNK and PI3K/Akt 
(unpublished data).  
!
!
2.2.3.2 Anti-carcinogenic benefits  
It is well known that there is a strong association of chronic inflammation with 
various types of cancer. Epidemiological studies and molecular studies have shown that 
inflammatory conditions increase the risk of malignancy. Chronic inflammation has 
tumor-promoting effects by various mechanisms including enhancing proliferation of 
malignant cells, promoting angiogenesis, boosting tumor metastasis, and altering tumor 
response to chemotherapeutic drugs(24). Accumulating studies have reported both in 
vitro and in vivo protective effects of PMFs against carcinogenesis. PMFs exert anti-
carcinogenic activities by induction of cell cycle arrest and cellular apoptosis, inhibition 
of cell proliferation, cancer cell mobility, angiogenesis and metastasis processes(57).  
NBT has been found to exert various protective effects against multiple cancers in 
animal models, such as gastric(12), colon(14-16), and prostate(16) cancer. In particular, 
previous studies have showed that dietary administration of NBT effectively suppressed 
colon carcinogenesis in three different colon cancer animal models(14-16). Suzuki et al. 
reported that 0.01% or 0.05% of NBT significantly decreased the incidence of colonic 
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adenocarcinoma, PCNA-labeling index, and levels of PGE2, while increased the 
apoptotic index in AOM-induced large bowel carcinogenesis in F344 rats(14). Miyamoto 
et al. reported that 0.01% of NBT decreased the incidence and number of colonic tumors 
and serum levels of leptin in AOM/DSS-induced colon carcinogenesis in ICR mice(15). 
Tang et al. reported that 0.05% of NBT trended to suppress PhIP-induced development of 
colonic aberrant crypt foci (ACF) in F344 rats(16). Together, these studies suggested that 
dietary feeding of NBT generally inhibited colon carcinogenesis induced by colon 
carcinogens in vivo.  
Recently, we found that the colonic level of NBT was about 20-fold lower than 
the total colonic level of its major metabolites. Cell culture studies demonstrated that the 
colonic metabolites of NBT significantly inhibited the growth of human colon cancer 
cells, caused cell cycle arrest, induced apoptosis, and profoundly modulated signaling 
proteins related with cell proliferation and cell death. All of these effects were much 
stronger than those produced by NBT alone, suggesting that the chemopreventive effects 
of orally administered NBT against colon carcinogenesis were closely associated with its 
colonic metabolites that had potent anti-cancer effects(47). Similarly, we found that the 
major metabolites of NBT in mouse lung after long-term oral administration also showed 
superior inhibitory effects than those produced by NBT alone in human nonsmall cell 
lung cancer (NSCLC) cells (unpublished data). These findings indicated that metabolites 
of PMFs generated in the body after oral ingestion may play principal roles in the 
biological activities of PMFs.  
Our previous studies have demonstrated that 5DT, one of important 5-
hydroxylated PMFs, exhibited superior anticancer potential than their counterparts 
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against multiple types of cancers(18, 19). Qiu et al. reported that 5DT showed significant 
groweth inhibitory effects on human colon cancer cells by inducing G2/M phase cell 
cycle arrest and extensive cellular apoptosis(19). Charoensinphon et al. suggested that 
5DT inhibited human NSCLC cells growth, and modulated the expression levels of 
various proteins related with cancer, such as p53, p21,!caspase-3, cleavage of PARP, 
Cdk-1 and cyclin B1. And IC50 of 5DT on different NSCLC cells were about 56-79 folds 
higher than those of its counterpart TAN(18).  
5DN is another important 5-hydroxylated PMF, that has been demonstrated the 
anti-carcinogenic properties against lung and colon cancer(19, 46, 58). We recently 
isolated and identified three different demethylated metabolites of 5DN from mouse urine 
by high liquid chromatography. We also found that these 5DN metabolites produced 
stronger growth inhibitory effects than their parental compound, 5DN on human colon 
cancer cells. For example, treatment of 5DN at 10 µM for 72 h only showed 37.2% 
inhibition on SW620 cells. However, IC50 of 5,3′-didemethylnobiletin after 72 h of 
treatment was as low as 0.12 µM. These results suggested that demethylation at 3′ 
position may dramatically enhance the growth inhibitory effects of 5DN against colon 
cancer cells(46). 
!
2.2.3.3 Anti-atherosclerosis benefits  
 Strong evidence indicates low-density lipoproteins (LDL) oxidation is 
crucial for atherogenesis. PMFs with strong antioxidant properties have been 
demonstrated to reduce hepatic production of cholesterol!containing lipoproteins 
resulting in the reduction of total cholesterol in plasma and consequently decrease 
of the risk of cardiovascular diseases(57). TAN has been shown to decrease the 
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total cholesterol in plasma, modulate apoB-containing lipoprotein metabolism, 
and reduce the levels of triacylglycerol, very low-density lipoproteins (VLDL) 
and LDL in HepG2 cells(59, 60).   
 Research on the anti-atherosclerosis activity of NBT showed that NBT 
was able to prevent plaque formation during atherosclerosis in THP-1 human 
monocytic cells by reducing mRNA expression of lectin-like, ox-LDL receptor-1 
(LOX-1), suppressing the phosphorylation of ERK and JNK, as well as inhibiting 
the nuclear translocation of AP-1(61). Another study reported that NBT 
significantly diminished the circulating concentrations of VLDL and LDLs in the 
blood, and inhibited macrophage-derived foam-cell formation(62). It can be 
concluded that the anti-inflammatory properties of PMFs may play an essential 
role in the prevention of atherosclerosis.  
Recently studies compared the anti-atherosclerosis effects of NBT and its major 
metabolite 3', 4'-didemethylnobiletin in THP-1 cells, and demonstrated that both 
metabolites had stronger anti-atherosclerosis effects than NBT due to its greater 
antioxidant properties against LDL oxidation and superior inhibitory effects on 




2.3 Combination therapy 
2.3.1 Introduction to combination therapy 
Accumulating studies have suggested that combination of cancer 
chemopreventive agents may produce enhanced protective effects against carcinogenesis 
than each individual agent alone. This combination regimen would be most 
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advantageous, if the chemopreventive agents used target different molecular sites and 
have differnet potential toxicities. The enhanced efficacy by the combination can also 
decrease the required dosage for each single agent in the combination, which in turn may 
reduce the potential toxicity and/or side effects from high-dose administration(22). 
As a cancer of high incidence, colon cancer has been frequently investigated as an 
important target of combination regimen. There are growing number of studies suggest 
that dietary bioactive components in combination may synergistically enhance the 
chemopreventive effects of individual component alone against colon carcinogenesis in 
the last two decades. Challa et al. reported that green tea and phytic acid in combination 
significantly decreased the aberrant crypt foci (ACF) incidence in AOM-treated rats(64). 
Xu et al. reported that the combination of curcumin and green tea catechins showed a 
significant reduction in ACF numbers, tumor incidence and cell proliferation in 
dimethylhydrazine-induced rats(65). Bose et al. demonstrated that fish oil plus (−)-
epigallocatechin-3-gallate reduced the tumor occurrence, number of large tumors, levels 
of PGE2, nuclear β-catenin and phosphorylated Akt in Apc Min/+ mouse model(65).  
Combination regimen has been suggested as a promising strategy for cancer 
prevention and treatment. However, information on the efficacy of this regimen in 
humans is still lacking. Moreover, only small fraction of combination studies analyzed 
combination index by using statistical methods to determine if the interactions among 
different agents were synergistic or not. Therefore, combination index-based standard 
protocols for combination studies should be established. 
 
2.3.2 Introduction to atorvastatin 
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Atorvastatin (ATST, commercially sold as Lipitor®!or Torvast®, Figure 2.6) is a 
member of statins family, which is a drug class used mainly for lowering blood 
cholesterol and for prevention of cardiovascular disease. Statins work by inhibiting 3-
hydroxy-3-methyl-glutaryl CoA reductase (HMG-CoA reductase); a rate-limiting enzyme 
found in liver that plays critical role in cholesterol biosynthesis in the body(66).!Lipitor® 
became the top-selling statin for more than one decade. Nowadays, it is still a widely 
prescribed cholesterol-lowering medicine. Besides its lipid-lowering effect, observational, 
preclinical and clinical studies have suggested that ATST can prevent colon 
carcinogenesis in human(66).!!
Mevalonate, a major product of HMG-CoA reductase activity, is the precursor for 
some intermediate products such as farnesyl pyrophosphate and geranylgeranyl 
pyrophosphate, which further isoprenylate various small GTPase proteins including the 
Ras/Rho!superfamily. The isoprenylation is necessary for cytosol-to-membrane 
translocation of these small GTPase proteins and thus become functional(67, 68). Ras 
homolog gene family, member A (RhoA) is a major member of Ras/Rho!superfamily that 
has been proven to be involved in cellular adhesion, proliferation and apoptosis(69, 70).!
In vitro study on HCT116 and HT29 human colon cancer cell lines proposed that ATST 
modulated HMG-CoA reductase and geranylgeranylation of small G-protein, such as k-





Figure 2.6  Chemical structure of atorvastatin (ATST) 
 
2.3.3 Potential enhancement of chemopreventive effect by using atorvastatin 
in combination with bioactive dietary compounds and/or drugs 
In the past decade, accumulating studies have shown that combination of ATST 
with other dietary agents and/or drugs can exert enhanced anti-cancer effects both in vitro 
and in vivo against various cancers, including colon(72, 73), lung(74, 75) and prostate 
cancer(76, 77).  
Xiao et al. reported that combination of ATST and celecoxib (a COX-2 selective 
NSAID) synergistically inhibited the growth of HT29 and HCT116 human colon cancer 
cells via inducing G0/G1 cell cycle arrest and apoptosis, and modulating the membrane 
localization of small G-proteins. They comfirmed that the enhanced bioactivities of 
ATST/celecoxib were synergistic by using isobologram analysis(72). Lu et al. 
investigated the possible synergistic inhibitory effects of ATST plus green tea 
polyphenols in H1299 and H460 lung cancer cells and a mouse lung tumorigenesis model. 
They found that the individual agents did not show significant anti-carcinogenic effects in 
animal model, however, low-dose co-treaments of ATST/green tea polyphenols 
effectively reduced the tumor multiplicity and tumor burden. In vitro study further 
revealed that the synergistic growth inhibitory effects of the co-treatment against lung 
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tumorigenesis were asscoiated with decreased levels of antiapoptotic protein Mcl-1, as 
well as increased cellular apoptosis and levels of proapoptotic proteins cleaved caspase-3 
and cleaved poly(ADP)-ribose polymerase caused by the co-treatment(74). Zheng et al. 
reported that ATST and celecoxib in combination at lower dose than each individual 
agent alone showed a more potent effect in inhibiting the progression of androgen-
dependent LNCaP xenograft prostate tumors to androgen independence(76). ! !
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                                                CHAPTER 3 
 CHEMOPREVENTIVE EFFECTS OF NOBILETIN AND ITS METABOLITES 
ON COLON CARCINOGENESIS 
 
3.1 Introduction 
 !Colon cancer is one of the major causes of cancer death and poses a serious 
threat to human health. It is well known that there is a strong association between 
inflammation and multiple types of cancers including colon cancer (24). Both referral 
center studies and population-based studies have demonstrated that patients with 
inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease are at an 
significantly increased risk of colon cancer as compared to the general population (78).!
Inflammation promotes carcinogenesis by various mechanisms including enhancing 
proliferation of malignant cells, promoting angiogenesis, boosting tumor metastasis, and 
altering tumor response to chemotherapeutic drugs (24). Accumulating evidence showed 
that certain dietary compounds have anti-inflammatory and anti-carcinogenic effects, and 
they can be potentially utilized as chemopreventive agents against inflammation-
associated colon carcinogenesis (7).!!
Polymethoxyflavones (PMFs) is a unique class of flavonoids mainly found in 
citrus fruits (9). Nobiletin (5,6,7,8,3',4'-hexamethoxyflavone, NBT) is a major citrus 
PMF. Previous studies have demonstrated a wide range of beneficial activities of NBT, 
including anti-inflammation (10, 11, 50), anti-cancer (12-16), and anti-atherosclerosis 
(17). NBT has shown various protective effects against different cancers in animal 
models, such as gastric (12), colon (14-16), and prostate (16) cancers. In particular, 
dietary administration of NBT was shown to suppress colon carcinogenesis in different 
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rodent models (14-16). Suzuki et al. reported that NBT inhibited AOM-induced colon 
carcinogenesis in rats (14). Miyamoto et al. demonstrated that NBT inhibited AOM/DSS-
induced colon carcinogenesis in mice, and this protective effect was associated with 
down-regulation of leptin (15). Tang et al. showed that NBT suppressed PhIP-induced 
formation of aberrant crypt foci in the rat colon (16). Together, these studies suggested 
that dietary administration of NBT generally inhibited chemically induced colon 
carcinogenesis in rodents.  
A growing body of evidence suggested that biotransformation played critical roles 
in the biological activities of orally administered compounds (20, 21). The metabolites 
generated in the body by the biotransformation may have more potent bioactivities in 
comparison with the parent compound (39, 40). Moreover, oral administration of a parent 
compound may result in higher levels of metabolites than the parent compound in certain 
tissues. Therefore, under the aforementioned circumstance, the metabolites, rather than 
the ingested parent compound, may exhibit dominant biological effects in those tissues 
(40). Previously, the colon cancer chemopreventive effects of NBT observed in rodent 
models were ascribed to NBT itself (14-16). There is no detailed information available 
about the role of biotransformation in the chemopreventive effects of NBT in the colon. 
To better understand the biological activities of NBT, we systematically investigated!the 
inhibitory effects of dietary NBT on colitis-associated colon carcinogenesis in 
AOM/DSS-treated CD-1 mice; identified and quantified major colonic metabolites of 
NBT in the mice, and elucidated the inhibitory effects of these metabolites on human 




3.2 Materials and Methods 
3.2.1 Animals, diets and experimental procedure 
The protocol for the animal experiment was approved by Institutional Animal 
Care and Use Committee of the University of Massachusetts Amherst (# 2014-0079). The 
male CD-1 mice (5 week old) were obtained from Charles River Laboratories 
(Wilmington, MA, USA). Upon arrival, the mice were kept in a temperature-controlled 
animal room (23°C) with humidity of 65–70%, fixed day/night cycle (12 h light), and 
free access to water and AIN93G diet for 2 week for acclimation. Mice were then 
randomly divided into two groups (control group and NBT group, 20 mice each) and 
were given one intraperitoneal injection of AOM (12 mg·kg-1 body weight) in saline. 
After 1 week, 1.5% DSS (molecular weight: 36,000–50,000, International Lab, Chicago, 
IL, USA) was administered in the drinking water for 4 days followed by 1 week of pure 
water for recovery, and this cycle was repeated four times.!Control group was fed with 
AIN93G diet, while NBT group was fed with AIN93G diet containing NBT (0.05 wt% in 
diet) starting at one week after the AOM injection until the end of study.!All mice were 
sacrificed by CO2 asphyxiation at 20 week after AOM injection.!The liver and spleen 
were removed and weighed.!After measurement of the length, the entire colons were 
opened longitudinally, rinsed with phosphate-buffered saline (pH 7.4). The whole colon 
weight was measured and the colons were inspected under a dissection microscope. 
Number and size of tumors were measured using an ocular micrometer. The sizes of 
tumors were determined by the following formula: tumor volume (mm3) = L  W2 / 2, 
where L is the length and W is the width of the tumor(79). Then the colons were cut into 
two pieces longitudinally. Half of the colon was fixed in 10% buffered formalin (pH 7.4) 
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for 24 h for further histopathological and immunohistochemical analysis. The other half 
of the colon was stored at -80°C for ELISA, qRT-PCR, and HPLC analysis. 
 
3.2.2 Histopathological and immunohistochemical analysis 
Formalin fixed colon tissues were processed for paraffin-embedding, sectioning, 
and haematoxylin and eosin (H&E) staining as we previously described (80). Based on 
H&E staining, histological alterations such as mucosal ulceration, dysplasia and 
carcinoma were evaluated!under a microscope (100×) according to the criteria previously 
reported (81). Carcinoma was defined as a high-grade dysplasia of colonic mucosa that 
had invaded beyond the muscularis mucosa and into the submucosa.!
Immunohistochemical analysis was conducted on the colon tissue sections as we 
previously described (80, 82). Cell proliferation in the colonic tissue was measured by 
staining with the antibodies against proliferating cell nuclear antigen (PCNA).!Apoptotic 
cells were determined by staining with antibodies against cleaved caspase-3. Antibodies 
were obtained from Cell Signaling Technology, Inc. (Beverly, MA, USA). 
 
3.2.3 Enzyme-linked immunosorbent assay (ELISA) and real-time qRT-PCR 
Analysis 
Colonic mucosa were scraped and homogenized in a phosphate buffer solution 
containing 0.4 M NaCl, 0.05% Tween-20, 0.5% BSA, 0.1 mM benzethonium, and 1% 
protease inhibitor cocktail (Boston Bioproducts, Ashland, MA, USA). The homogenates 
were centrifuged at 10,000g for 30 min at 0°C. The supernatant was used for 
quantification of cytokines, i.e. interleukin 1β (IL-1β), interleukin 6 (IL-6) and tumor 
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necrosis factor-α (TNF-α) by ELISA kits (R&D Systems, Minneapolis, MN, USA) 
according to the manufacturer's instructions. Real-Time qRT-PCR analysis was 
conducted as previously described (53). The primer pairs were synthesized by Integrated 
DNA Technologies, Inc. (Coralville, IA, USA) with the following primers: IL-1β F: 5′-
ACCTGCTGGTGTGTGACGTT-3′, R: 5′-TCGTTGCTTGGTTCTCCTTG-3′; IL-6 F: 
5′-GAGGATACCACTCCCAACAGACC-3′, R: 5′-
AAGTGCATCATCGTTGTTCATACA-3′A; TNF-α F: 5′-
AGCACAGAAAGCATGATCCG-3′, R: 5′-CTGATGAGAGGGAGGCCATT-3′; β-actin 
F: 5′-AAGAGAGGCATCCTCACCCT-3′, R: 5′-TACATGGCTGGGGTGTTGAA-3′ 
(83). The copy number of each transcript was calculated with respect to the β-actin copy 
number, using the 2−ΔΔCt method (84).  
 
3.2.4 Determination of colonic levels of NBT and its metabolites by HPLC 
Colonic mucosa samples were homogenized in PBS and extracted with equal 
volume of ethyl acetate for three times. Pooled ethyl acetate fractions were dried under 
vacuum and dissolved in 50% methanol. Identification and quantification of NBT and its 
metabolites were carried out by an HPLC with an electrochemical detector using!our 
previously published method (46, 85). NBT, M1, M2, and M3,!with purity greater than 
98%, were used as external standards to identify and quantify NBT, M1, M2, and M3. 
Tangeretin was used as an internal standard. NBT and tangeretin were from Sigma-
Aldrich (St. Louis, MO, USA). M1, M2, and M3 were!synthesized as described 




3.2.5 Analysis of cell viability, cell cycle and apoptosis 
Assays for cell viability, cell cycle and apoptosis were conducted as we 
previously described (19, 72, 86). In brief, human colorectal cancer cells, HCT116 and 
HT29 (ATCC, Manassas, VA, USA) were seeded in 96-well plates. After 24 h, cells were 
treated with serial concentrations of NBT and its metabolites, and the cell viability was 
quantified by MTT method (19, 72, 86). HCT116 and HT29 cells were seeded in 6-well 
plates for cell cycle and apoptosis analysis. After 24 h of incubation for cell attachment, 
cells were treated with serial concentrations of NBT and its metabolites in serum 
complete media. After the treatment, media containing any floating cells were harvested 
and combined with adherent cells that were detached by brief trypsinization. Cell pellets 
were washed with 1 mL of ice-cold PBS then subject to cell cycle and apoptosis analysis 
by flow cytometry as we described previously (19, 72, 86). DMSO was used as vehicle to 
deliver NBT and its metabolites to the cells. The final concentration of DMSO in all 
experiments was 0.1% v/v in cell culture media. 
 
3.2.6 Immunoblotting 
Cells were seeded in 150 mm culture dishes. After 24 h of incubation for cell 
attachment, cells were treated with NBT (40 µM), M1 (40 µM), M2 (40 µM) or M3 (20 
µM). After another 24 or 48 h of incubation, cells were washed with ice-cold PBS, and 
collected with cell scrapers. Whole cell lysates were prepared and then subjected to 
Western blotting analysis as we previously reported (19, 53, 72, 86). Antibodies for 
p21Cip1/Waf1, cyclin D1, cleaved caspase-3, cleaved caspase-9, and cleaved poly ADP 
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ribose polymerase (PARP) were purchased from Cell Signaling Technology (Beverly, 
MA, USA). Anti-β-actin antibody was from Sigma-Aldrich (St. Louis, MO, USA). 
 
3.2.7 Statistical analysis 
All data were presented as mean ± SD. Student’s t-test was used to test the mean 
difference between two groups. Analysis of variance (ANOVA) model was used for the 
comparison of differences among three or more groups.  A p value <0.05 was considered 
to be statistically significant. 
 
3.3 Results and Discussion 
3.3.1 Oral administration of NBT decreased the incidence and multiplicity of colonic 
tumors in AOM/DSS-treated mice 
AOM/DSS-treated mice were used to determine chemopreventive effects of 
dietary NBT (0.05 wt% in AIN93G diet) on colitis-associated colon carcinogenesis. 
Injection of a colon carcinogen AOM in combination with cyclic administration of DSS 
in drinking water resulted in the development of colitis, colorectal dysplasia, and cancer 
(87). Body weight was monitored twice a week as an indicator of potential toxicity of 
NBT, and no difference was found between NBT-treated group and the control during the 
whole experimental period (final body weights were shown in the Table 3.1). There was 
no difference in the weight of liver and spleen between the two groups (Table 3.1), and 
no apparent behavioral or appearance difference was observed either, suggesting no 
noticeable toxic effects caused by dietary feeding of NBT to the mice. Colon 
weight/length ratio is correlated with the severity of colitis and therefore is an indicator of 
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levels of inflammation in the colon (88). As shown in Table 1, compared to the control 
group, dietary treatment with NBT significant prevented the shortening of colon length 
and reduced the elevated colon weight/length ratio caused by AOM/DSS. The AOM/DSS 
treatment resulted in 100% incidence of colon tumors and 4.97 ± 1.01 colonic tumors per 
mouse. Dietary administration of NBT significantly decreased the tumor incidence by 40% 
and tumor multiplicity by 71% (4.97 ± 1.01 vs. 1.45 ± 0.60). H&E staining showed that 
the colonic mucosa of the control group presented typical inflammatory and cancerous 
characteristics such as formation of dysplasia, distortion of crypts structure and 
infiltration of inflammatory cells (Figure 3.1A). In contrast, the colonic mucosa of NBT-
treated group appeared to largely maintain the histological characteristics of normal 
mucosa (Figure 3.1B). These results demonstrated that NBT effectively inhibited 





















3.3.2 Oral administration of NBT reduced cell proliferation, induced apoptosis, and 
decreased the levels of pro-inflammatory cytokines in the colon of AOM/DSS-
treated mice 
Uncontrollable cell proliferation is an important feature of colon carcinogenesis. 
Proliferating cell nuclear antigen (PCNA) is a cofactor of DNA polymerase δ. The 
expression of PCNA is increased during G1 phase through S phase of the cell cycle; and 
it plays a critical role in regulating DNA replication (89). PCNA therefore is often used 
as a key marker for cell proliferation (90). Immunohistochemical analysis showed high 
number of PCNA positive colonocytes within the colonic mucosal crypts of AOM/DSS-
treated control mice (Figure 3.1C), indicating a high cell proliferation rate. However, 
dietary treatment with NBT decreased the number of PCNA positive colonocytes by 69% 
(Figure 3.1D and 3.1G). Apoptosis is a major type of programed cell death, and it plays 
an essential role in balance of death of cancerous cells and survival of normal cells in 
prevention and treatment of cancer (25). Induction of apoptosis in cancerous cells is!
considered an effective strategy for cancer chemoprevention. Caspase-3 is a major 
regulator of apoptosis, and it can be activated (cleaved) by other initiator caspases such as 
caspase-9. Cleaved caspase-3 can then further cleave Poly ADP-ribose polymerase 
(PARP), leading to the loss of DNA repair functions of cancerous cells, and then cell 
death (91). As shown in Figure 3.1E and 3.1F, colonic tumors from the control group 
showed low number of cleaved capase-3 positive cells, while higher number of cleaved 
caspase-3 positive cells (2.3-fold increase, Figure 3.1G) were observed in the colonic 
tumors of NBT-treated group. These results demonstrated that dietary treatment with 
NBT significantly decreased abnormal cell proliferation and induced apoptosis in the 
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colonocytes of AOM/DSS-treated mice, which is believed to contribute to the cancer 
preventive effects of NBT against colon carcinogenesis.  
Accumulating studies have demonstrated that improper up-regulation of pro-
inflammatory cytokines such as interleukin 1β (IL-1β), interleukin 6 (IL-6), and tumor 
necrosis factor-α (TNF-α) can accelerate the process of colon carcinogenesis (92, 93). 
Using ELISA, we determined the effects of dietary treatment with NBT on the 
AOM/DSS-induced production of pro-inflammatory cytokines in colonic mucosa. As 
shown in Figure 3.2A, NBT treatment resulted in significant decreases in the levels of IL-
1β, IL-6 and TNF-α by 92%, 69% and 51%, respectively, compared to those of the 
control group. Next, we determined the effects of NBT on the mRNA expression levels 
of pro-inflammatory cytokines by Real-Time qRT-PCR analysis. As shown in Figure 
3.2B, the mRNA expression levels of IL-1β, IL-6, and TNF-α were significantly reduced 
by NBT treatment by 69%, 45%, and 65%, respectively, in comparison with those found 
in the control mice. Together, our results showed that oral administration of NBT 
inhibited the colon carcinogenesis at least partially by reducing cell proliferation, 
inducing apoptosis, and suppressing the expression levels of pro-inflammatory cytokines 








Figure 3.1. Histological characterization of colonic mucosa and tumors of AOM/DSS-
treated mice. (i) H&E staining of colonic tissues of the control (A) and NBT-treated (B) 
groups (Magnification: 100×); (ii) PCNA staining of colonic mucosa of the control (C) 
and NBT-treated (D) groups (Magnification: 400×); (iii) Cleaved caspase-3 staining of 
colonic tumors of the control (E) and NBT-treated (F) groups (Magnification: 400×); (iv) 
Quantification of PCNA-positive and caspase-3 positive cells in colonic mucosa and 





Figure 3.2. Effects of NBT treatment on protein levels (A) and mRNA levels (B) of IL-
1β, IL-6, and TNF-α in the colonic mucosa of AOM/DSS-treated mice. Colon tissues 
samples were randomly collected from the middle and distal colon, and then subjected to 
ELISA or qRT-PCR analysis. Data are shown as the mean ± SD of three independent 
experiments. The amount of IL-1β, IL-6, TNF-α mRNA expression was normalized to 
that of β-actin. * indicates statistically significant differences from the control group (p < 





3.3.3 Identification and quantification of colonic metabolites of NBT in mice 
It is well recognized that the in vivo metabolic fate of dietary flavonoids is critical 
for their biological activities. We and others have reported that orally administered PMFs, 
such as NBT, tangeretin and 5-demethylnobiletin, undergo extensive biotransformation to 
produce various metabolites (44-46, 49, 85). Particularly, three major metabolites were 
identified in the urine of CD-1 mice after oral administration of NBT (44, 45).  The 
structure of the three metabolites were shown in Figure 3.3A, and they are 3'-
demethylnobiletin (M1), 4'-demethylnobiletin (M2), and 3', 4'-didemethylnobiletin (M3), 
Interestingly, studies have demonstrated that these metabolites of NBT had potent 
biological activities, including anti-inflammation (45) and anti-atherogenesis (63). For 
example, in RAW264.7 macrophages, three metabolites of NBT, especially M2 and M3, 
showed strong anti-inflammatory effects such as suppressing LPS-induced production of 
nitric oxide and gene expression of iNOS and COX-2 (45). Moreover, in THP-1-derived 
macrophages, M3 showed a strong protective effect against atherogenesis due to its 
antioxidant activity against LDL oxidation and inhibition on!monocyte-to-macrophage 
differentiation and foam cell formation (63). Most importantly, the aforementioned 
beneficial bioactivities of three metabolites were shown to be even stronger than those 
produced by their parent compound, NBT.  
An important goal of this study was to establish the role of biotransformation in 
the chemopreventive effects of NBT against colitis-associated colon carcinogenesis. In 
order to do so, the identity and abundance of colonic metabolites of NBT were needed. 
We hypothesized that the urinary metabolites (M1, M2, and M3) of NBT can also be 
found in the colonic mucosa of mice after oral administration of NBT. To confirm this 
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hypothesis, we conducted HPLC analysis on colonic mucosa samples harvested from 
NBT-fed mice and the control mice (46, 85). The results showed that there were three 
major metabolites of NBT in the colonic mucosa of NBT-fed mice. We chemically 
synthesized M1, M2, and M3 (purity greater than 98%) and used them as chemical 
standards for HPLC and mass spectroscopy analysis (46, 85). It was observed that the 
colonic metabolites of NBT showed identical retention times and!electrochemical 
responses as M1, M2 and M3 standards. Mass spectroscopy results also confirmed that 
three colonic metabolites of NBT showed identical molecular weights as M1, M2, and 
M3, respectively. These results demonstrated that M1, M2, and M3 were the major 
metabolites of NBT in the colonic mucosa of the mice fed with NBT. The exact 
mechanism for the formation of these colonic metabolites are not known, and it is likely 
that their formation is the result of phase I & II metabolism as well as biotransformation 
by gut microbiome. 
We further quantified the levels of NBT and its metabolites in the colonic mucosa 
of NBT-fed mice by HPLC (46, 85). As shown in Figure 3.3B, the colonic levels of NBT, 
M1, M2 and M3 were 2.03, 3.28, 24.13, and 12.03 nmol/g of tissue, respectively. It is 
noteworthy that the levels of three metabolites M1, M2, and M2 were 1.6-, 11.9- and 5.9-
fold higher than that of NBT in the colonic mucosa, respectively, and the level of NBT 
only accounted for less than 5% of total levels of NBT and three metabolites. This is very 
useful information because it indicated that colonic metabolites of NBT might play more 
important roles than NBT itself in the inhibition of colon carcinogenesis after oral 
administration of NBT, due to their much greater abundance than NBT in the colonic 
mucosa. Overall, for the first time, we identified M1, M2 and M3 as three major 
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metabolites of NBT found in the colonic mucosa of the mice after long-term oral 
administration of NBT. Most importantly, we found that the major forms of NBT in the 
colonic mucosa were its metabolites rather than NBT itself, suggesting the importance of 











































Figure 3.3 (A) Chemical structure of NBT and its metabolites M1, M2, and M3. (B) 
Representative HPLC chromatogram of NBT, M1, M2, and M3 in the colonic mucosa 
samples. NBT was detected by UV, and M1, M2, and M3 were detected by 
electrochemical detection at 400 mv. (C) Quantification of NBT and its metabolites in the 
colonic mucosa of mice fed with NBT by HPLC analysis. Different notations in the bar 





3.3.4 Colonic metabolites of NBT had stronger inhibitory effects than NBT on the 
growth of human colon cancer cells 
To compare anti-cancer potential of NBT and its colonic metabolites, we 
determined the inhibitory effects of NBT, M1, M2, and M3 (at a series of concentrations) 
on the growth of two human colon cancer cell lines, HCT116 and HT29. As shown in 
3.4A, all four compounds showed dose-dependent inhibitory effects on both cell lines 
after 72 hours of treatment. Overall, M2 and M3 showed stronger inhibitory effects than 
NBT, especially M3, while M1 showed similar or weaker inhibitory effects than NBT.  
Previously, we studied the inhibitory effects of 5-demethylnobiletin (another 
important PMF) and its urinary metabolites in human colon cancer cells SW620 and 
SW480. Our results demonstrated that demethylation at 3'-, 4'-, or both 3'-and 4'-positions 
of PMF might significantly alter its biological activities (46). In this study, we found that 
M3 showed strongest inhibitory effects on human colon cancer cells, indicating that 
demethylation at both 3'-and 4'-positions enhanced the inhibitory effects of NBT on colon 
cancer cells. Additionally, M3 has been reported to have stronger inhibitory effects 
against inflammation and atherogenesis than NBT (45, 63). It was observed that colonic 
metabolites M2 and M3 showed stronger inhibitory effects on human colon cancer cells 
than their parent compound NBT, and the levels of M2 and M3 in the colonic mucosa of 
NBT-fed mice were about 12- and 6-fold higher than that of NBT. These results 
suggested that M2 and M3 might have played critical roles in the anti-carcinogenic 
activities of NBT observed in the NBT-fed mice.  
In order to establish the anti-colon cancer effects of NBT and its metabolites in a 
physiologically relevant manner, we determined their inhibitory effects on colon cancer 
!
52!
cells at the concentrations found in the mouse colonic mucosa after oral consumption of 
NBT (Figure 3.4B). If we assumed that 1-gram of colonic tissue gave 1 mL of volume, 
the concentrations of NBT, M1, M2, and M3 in the colonic mucosa were 2.03, 3.28, 
24.13, and 12.03 µM, respectively. As shown in Figure 3.4B, after 96 hours of treatments 
with the compounds at these concentrations, NBT or M1 did not show any significant 
inhibition on the HCT116 or HT29 cells. In contrast, M2 caused 45% and 33% inhibition, 
while M3 caused 30% and 9% inhibition on HCT116 and HT29 cells, respectively. 
Moreover, the combination of M1, M2, and M3 resulted in 64% and 62% inhibition on 
HCT116 and HT29 cells, respectively. Most interestingly, the combination of all four 
compounds (NBT, M1, M2, and M3) did not produce stronger inhibitory effects in 
comparison with the combination of M1, M2, and M3. Overall, our results demonstrated 
that colonic metabolites of NBT played more important roles than NBT itself in 









Figure 3.4 (A) Growth inhibitory effects of NBT, M1, M2 and M3 on HCT116 and 
HT29 human colon cancer cells. Cells were seeded in 96-well plates, and after 24 h of 
incubation, cells were treated with serial concentrations of NBT and its metabolites. After 





SD (n = 6).!(B) Growth inhibitory effects of NBT, M1, M2, M3, NBT+M1+M2+M3, and 
M1+M2+M3 on HCT116 and HT29 human colon cancer cells. The concentrations of 
these compounds and their combination were the same as those found in the colonic 
mucosa of mice fed with NBT (see Figure 3.3B). Cells were seeded in 96-well plates, and 
after 24 h of incubation, cells were treated with NBT, its metabolites and their 
combinations. After 96 h of incubation, cell viability was measured by MTT assay as 
described. Data are shown as mean ± SD (n = 6). Different notations in the bar charts 




3.3.5 Colonic metabolites of NBT had stronger effects in inducing cell cycle arrest 
and apoptosis than NBT  
To further characterize the mode of action of NBT and its metabolites in 
inhibiting the growth of colon cancer cells, we determined their effects on cell cycle and 
apoptosis by flow-cytometry. As shown in Figure 3.5A, treatments with NBT (40 µM) or 
M2 (40 µM) for 24 hours caused cell cycle arrest at G0/G1 phase in both HCT116 and 
HT29 cells, and the effects of M2 were stronger than those of NBT. In contrast, M1 (40 
µM) and M3 (20 µM) led to cell cycle arrest at G2/M and S phases in HCT116 cells, and 
G2/M and G0/G1 phases in HT29 cells, respectively. Our results showed that different 
colonic metabolites of NBT had distinct effects on cell cycle progression of human colon 
cancer cells; suggesting different molecular mechanisms were involved in their actions.  
To determine if apoptosis contributed to the growth inhibitory effects of NBT and 
its metabolites, we performed Annexin-V/Propidium iodine double staining assay to 
evaluate the cellular apoptosis of HCT116 and HT29 cells. As shown in Figure 3.5B, 
after 48 hours of treatment, in comparison to the control cells, both early and late 
apoptotic cells were significantly increased by all four compounds in HCT116 cells. 
Treatments with NBT (40 µM), M1 (40 µM) and M2 (40 µM), and M3 (20 µM) increased 
early apoptotic cell population by 3.3-, 5.0-, 4.9-, and 7.6-fold compared to the control, 
respectively; while they increased late apoptotic cell population by 4.2-, 3.5-, 7.1-, and 
4.5-fold, respectively. Overall, all metabolites showed stronger effects in inducing 
apoptosis (early plus late) than NBT in HCT116 cells. In HT29 cells, treatments with 
NBT (40 µM) and M3 (20 µM) induced significant apoptosis with the effects of M3 
being stronger than those of NBT. M1 (40 µM) and M2 (40 µM) did not cause significant 
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apoptosis in HT29 cells. These results demonstrated that NBT and its metabolites, 
especially M3 induced significant apoptosis in human colon cancer cells. It is noteworthy 
that the structure differences among NBT and its colonic metabolites are the number and 
position of demethylation, and these differences produced significant distinction in their 





Figure 3.5. Effects of NBT (40 µM), M1 (40 µM), M2 (40 µM) and M3 (20 µM) on!cell 
cycle progression (A) and apoptosis (B) of HCT116 and HT29 human colon cancer cells. 
Cells were seeded in 6-well plates for 24 h, and then treated with NBT and its 
metabolites. After 24 or 48h of treatments,!cells were harvested and subject to cell cycle 
and apoptosis analysis, respectively Data are shown as mean ± SD. Different notations in 




3.3.6 Colonic metabolites of NBT modulated expression of key signaling proteins 
related with cell cycle and apoptosis regulation  
To better understand the molecular mechanisms underlying the anticancer 
activities of NBT and its colonic metabolites, we analyzed the effects of NBT and its 
colonic metabolites on key signaling proteins related to cell cycle and apoptosis pathways 
in HCT116 cells by immunoblotting analysis. Cell cycle-related proteins p21Cip1/Waf1 and 
cyclin D1 were analyzed after 24 hours of treatment, and apoptosis-related proteins 
cleaved caspase-3, cleaved caspase-9, and cleaved PARP were analyzed after 48 hours of 
treatment. As shown in Figure 3.6, NBT and all three colonic metabolites caused 
significant increases of p21Cip1/Waf1 expression levels, while only M2 decreased the level 
of cyclin D1 significantly. The loss of regulated cell cycle and normal cell behavior is 
one of the important hallmarks of cancer. Cell cycle is tightly controlled by checkpoints, 
and different cyclin-CDK (cyclin-dependent kinase) complexes. p21Cip1/Waf1 is a key 
regulator of cell cycle that can inhibit CDK activities and thus control the cell cycle 
progression at G1 and S phase. The transition of cell cycle from G1 to S phase is mainly 
regulated by cyclin D-CDK4/6 complexes. Induction of p21Cip1/Waf1 can in turn cause the 
inactivation or degradation of cyclin D1, leading to cell cycle arrest in G0/G1 stage (33). 
Our results illustrated that M2-mediated G0/G1 cell cycle arrest is associated with 
induction of p21Cip1/Waf1 and reduction of cyclin D1. Although treatments with NBT, M1 
and M3 affected the protein levels of p21Cip1/Waf1, they did not significantly inhibit the 
level of cyclin D1. This may partially explain why NBT, M1, and M3 had weaker or no 




The evasion of apoptosis is one of the most common cellular abnormalities that 
may facilitate the development of various cancers (31). Activation (cleavage) of caspase-
9 and its downstream effector caspase-3 play critical roles in triggering cellular apoptosis. 
Cleavage of caspase-3 can lead to the activation (cleavage) of other key proteins, such as 
PARP, which can ultimately promote apoptosis by interfering chromatin condensation 
and DNA fragmentation(32). Our results showed that colonic metabolites of NBT 
strongly induced the activation of caspase cascade, including cleavage of caspase-3 and 
caspase-9, as well as their final protein target PARP in HCT116 cells, while NBT only 
induced the activation of caspase-9 and had no effect on caspase-3 or PARP (Figure 3.6). 
This finding is consistent with previous Annexin-V/PI double staining assay (Figure 
3.5B). Again, our results demonstrated that colonic metabolites of NBT had stronger 





Figure 3.6. Effects of NBT (40 µM), M1 (40 µM), M2 (40 µM) and M3 (20 µM) on cell 
cycle and apoptosis related signaling proteins in HCT116 human colon cancer cells. 
HCT116 cells were seeded in 10-cm dishes for 24 h, and then cells were treated with 
NBT and its metabolites.!After another 24 or 48 h of incubation, cells were collected for 
immunoblotting analysis as described.!The numbers underneath of the blots represent 
band intensity (normalized to β-actin, means of three independent experiments) measured 
by Image J software.!The SDs (all within ±15% of the means) were not shown. β-Actin 
was served as an equal loading control. * indicates statistical significance in comparison 




In conclusion, our results demonstrated that oral administration of NBT 
effectively inhibited colitis-associated colon carcinogenesis in AOM/DSS-treated male 
CD-1 mice.  For the first time, we identified and quantified major metabolites of NBT in 
the colonic mucosa, namely 3'-demethylnobiletin (M1), 4'-demethylnobiletin (M2), and 
3', 4'-didemethylnobiletin (M3). Moreover, the abundance of these metabolites were 
about 20-fold higher than that of their parent compound NBT in the colonic mucosa.  Our 
results further demonstrated that colonic metabolites of NBT had stronger anti-cancer 
effects than NBT, which was evidenced by their superior effects in inhibiting cancer cell 
growth, inducing cell cycle arrest and apoptosis, and modulating key signaling proteins. 
Together, our results showed that the chemopreventive effects of orally administered 
NBT against colon carcinogenesis were closely associated with its colonic metabolites 
that had potent anti-cancer effects.!This study provided a solid scientific basis for using 






ANTI-INFLAMMATORY EFFECTS OF 4'-DEMETHYLNOBILETIN 
(4DN), A MAJOR METABOLITE OF NOBILETIN 
!
4.1 Introduction 
It is well recognized that there is a strong association of inflammation with 
various types of diseases such as cancer. Epidemiological studies and molecular studies 
have shown that inflammatory conditions increase the risk of malignancy. Chronic 
inflammation has tumor-promoting effects by various mechanisms including enhancing 
proliferation of malignant cells, promoting tumor angiogenesis and metastasis, and 
altering tumor response to chemotherapeutic drugs (24). In tumor cells and inflammatory 
cells, eukaryotic transcription factor nuclear factor-kappa B (NF-κB) contributes to the 
activation of genes coding pro-inflammatory enzymes, such as induce inducible nitric 
oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), which in turn stimulates the 
expression of nitric oxide (NO) and prostaglandins, respectively. Prostaglandin E2 (PGE2), 
the major bioactive lipid derived from COX-2 activity, is a key inflammatory mediator 
that promote tumor growth and metastasis. Similarly, iNOS-mediated overproduction of 
NO can cause modifications and structure damage of DNA, and promote tumor 
angiogenesis (26). NF-κB also triggers the expression of pro-inflammatory cytokines, 
such as interleukin-1β (IL-1β). Besides NF-κB, activator protein 1 (AP-1) is another 
transcription factor that plays an important role in the regulation of the expression of 
genes responsible for inflammatory responses including iNOS and COX-2 (27). Nuclear 
factor erythroid 2-related factor 2 (Nrf2), a redox-sensitive transcription factor, 
translocates to the nucleus and triggers the expression of a set of phase II detoxification 
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and antioxidant enzymes including heme oxygenase-1 (HO-1) and NADH quinone 
oxidoreductase 1 (NQO1) when stimulated by pro-oxidant stimulus. In contrast to the 
pro-inflammatory effects of NF-κB and AP-1, Nrf2 was reported to inhibit abnormal 
inflammatory response (28), and alleviate adverse effects of LPS-induced NF-κB 
activation (29). Previous studies have shown that increased HO-1 and NQO1 expression 
contributed to the adaptive increase of cellular anti-oxidant and anti-carcinogenic 
capacity (30). Since Nrf2 and its downstream anti-oxidative enzymes play critical roles in 
down-regulation of inflammation, they are important targets for anti-inflammation 
remedy. 
Polymethoxyflavones (PMFs) are unique flavonoids mainly found in citrus fruits 
(9). Nobiletin is a major PMF and has been reported to have with a wide range of 
biological activities, including anti-inflammation (45, 53). In vitro studies showed that 
nobiletin inhibited LPS-induced production of NO and PGE2 in RAW 264.7 macrophages 
(53), and suppressed gene expression of pro-inflammatory cytokines including IL-1β, IL-
6 and TNF-α in J774A.1 macrophages (54). In vivo studies demonstrated that nobiletin 
inhibited TPA-induced skin inflammation (10) and suppressed dextran sulfate sodium-
induced colitis (15). 
Biotransformation plays critical roles in the biological activities of dietary 
components (20, 21).  A compound can be biotransformed to produce metabolites that 
may exhibit enhanced or reduced biochemical and pharmacological activities. We and 
others have studied biotransformation of polymethoxyflavones including nobiletin and 
identified their major metabolites in mice (44-47, 94). After oral administration, nobiletin 
was transformed to its demethylated metabolites such as 3'-demethylnobiletin, 4'-
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demethylnobiletin (4DN), and 3', 4'-didemethylnobiletin. Interestingly, 4DN was the 
most abundant metabolite, and its abundance was even much higher than that of nobiletin 
in certain tissues(47). Moreover, it has been reported that 4DN had stronger bioactivities 
than nobiletin such as anti-inflammation and anti-cancer effects (45, 47). However, the 
detailed information on anti-inflammatory effects of 4DN and its molecular mechanisms 
remains unknown. Therefore, the aim of this study was to determine!the inhibitory effects 
of 4DN on LPS-induced inflammation in RAW 264.7 macrophage cells and TPA-
induced skin inflammation model, and elucidate the underlying molecular mechanisms. 
 
4.2 Materials and methods 
4.2.1 Cell cultures and treatments 
RAW 264.7 cells were purchased from the American Type Culture Collection 
(ATCC, Rockville, MD, USA) and were cultured in RPMI-1640 media supplemented 
with 10% heat-inactivated FBS (Medistech, Herndon, VA, USA), 100 units/mL of 
penicillin, and 0.1 mg/ mL of streptomycin (Sigma-Aldrich, St. Louis, MO, USA) at 37 
°C with 5% CO2 and 95% air. 4DN was chemically synthesized as previously described 
(44, 46, 85). Chemical structure of NBT and 4DN was illustrated in Figure 4.1. 
Dimethylsulfoxide (DMSO) was used as the vehicle to deliver 4DN to the cells. The final 
concentration of DMSO in all experiments was 0.1% (v/v) in cell culture media. 
 
4.2.2 Cell viability and nitric oxide assay 
The cell viability was determined as previously described(58). RAW 264.7 cells 
(5 × 104 cells/well) were seeded in 96-well plates. After 24 h, cells were treated with 
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serial concentrations of 4DN in 200 µL of serum complete media. After 24 h treatments, 
cells were subject to MTT assay. Media were replaced by 100 µL of fresh media 
containing 0.1 mg/mL of MTT (Sigma-Aldrich, St. Louis, MO, USA). After 2 h of 
incubation, MTT-containing media were removed, and the reduced formazan dye was 
solubilized by adding 100 µL of DMSO to each well. After gentle mixing, the absorbance 
was monitored at 570 nm using a plate reader (Elx800TM absorbance microplate reader, 
BioTek Instrument, VT, USA).!The nitrite concentration in the culture media was 
measured as an indicator of NO production by the Griess reaction. The culture media 
were mixed with an equal volume of Griess reagent A and B (A: 1% sulfanilamide in 5% 
phosphoric acid, and B: 0.1% naphthylethylenediaminedihydrochloride in water). 
Absorbance at 540nm was measured by a plate reader, and concentrations of nitrite were 
calculated according to a standard curve constructed with sodium nitrite as a standard as 
we previously reported(53). 
 
4.2.3 ELISA for PGE2 and cytokines 
RAW 264.7 cells (5 × 106 cells/well) were seeded in 6-well plates. After 24 h, 
cells were treated with 1 µg/mL LPS alone or with serial concentrations of 4DN in 2 mL 
of serum complete media. After another 24 h of incubation, the culture media were 
collected and analyzed for PGE2, IL-1β and IL-6 levels by ELISA kits, according to the 
manufacturer's instructions (R&D Systems, Minneapolis, MN, USA).  
 
4.2.4 Western blotting analysis 
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Whole Cell lysate were prepared as previously described (53). RAW 264.7 cells 
were seeded in 10 mm culture dishes. After 24 h of incubation, cells were treated with 1 
µg/mL LPS alone or with serial concentrations of 4DN. After 24 h of incubation, the cells 
were harvested and extracted with RIPA lysis buffer ((Tris-HCl pH 7.2, 25 mM; SDS 
0.1%; Triton X-100 1%; sodium deoxycholate 1%; NaCl 0.15 M; EDTA 1 mM) (Boston 
Bioproducts, Ashland, MA, USA) containing 1% protease inhibitor cocktail. The nuclear 
and cytosolic fractions were prepared using NE-PER Nuclear and Cytoplasmic Extraction 
Kit (Thermo Fisher Scientific, Rockford, IL, USA). Protein concentrations were 
determined using the BCA method (Pierce, Rockford, IL, USA). The cell lysates were 
further subjected to Western blotting analysis as we previously described (53). 
Antibodies for iNOS, COX-2, p-IκBα, IκBα, PI3K, p-Akt, Akt, p-JNK, JNK, HO-1 and 
PARP were obtained from Cell Signaling Technology (Beverly, MA, USA). NF-κB p50, 
p65, c-Fos, c-Jun, p-PI3K, NQO1 and Nrf2 were obtained from Santa Cruz (Santa Cruz, 
CA, USA). Anti β-actin antibody was from Sigma-Aldrich. 
 
4.2.5 qRT-PCR analysis 
Real-Time qRT-PCR analysis was conducted as previously described(53). The 
primer pairs were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA, 
USA) with the following primers: iNOS F: 5′- TCC TAC ACC ACA CCA AAC-3′, R: 
5′- CTC CAA TCT CTG CCT ATC C-3′; COX-2 F: 5′- CCT CTG CGA TGC TCT 
TCC-3′, R: 5′- TCA CAC TTA TAC TGG TCA AAT CC-3′; HO-1 F: 5′-AAG AGG 
CTA AGA CCG CCT TC-3′, R: 5′-GTC GTC GTC AGT CAA CAT GG-3′; NQO1 F: 5′-
TCG GAG AAC TTT CAG TAC CC-3′, R: 5′-TGC AGA GAG TAC ATG GAG CC-3′; 
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GADPH F: 5′- TCA ACG GCA CAG TCA AGG-3′, R: 5′- ACT CCA CGA CAT ACT 
CAG C-3′. A minimum of three independent experiments was carried out, and each 
experiment had triplicate samples for each treatment. The copy number of each transcript 
was calculated with respect to the GADPH copy number, using the 2−ΔΔCt method(84).  
 
4.2.6 TPA-induced skin inflammation in mouse  
The protocol for the animal experiment was approved by Institutional Animal 
Care (permission number, 2011-0066) and Use Committee of the University of 
Massachusetts Amherst. Male CD-1 (5-6 wk-old) mice were purchased from Charles 
River Breeding Laboratories (Kingston, NY, USA). The mice were kept in our animal 
facility for at least 1 week for acclimation before use. Upon arrival, mice were kept in a 
temperature-controlled animal room (23°C) with free access to water and AIN93G diet 
and kept on a 12 h light, 12 h dark cycle. Mice were randomly divided into six groups 
(six animals each). Group 1, negative control; both ears of CD-1 mice in Group 1 were 
topically treated with 10 µL of acetone (vehicle) acetone 30 min prior to application of 
another acetone. Group 2, TPA control; both ears of CD-1 mice in Group 2 were 
topically treated with 10 µL of acetone 30 min prior to application of 2 nmol TPA in 10 
µL of acetone. Group 3-6, treatment groups; both ears of CD-1 mice in treatment groups 
were topically treated with NBT (2 µmol or 4 µmol) or 4DN (2 µmol or 4 µmol) in 10µL 
of acetone 30 min prior to application of 2 nmol TPA in 10 µL of acetone. All mice were 
sacrificed 6 h after TPA (acetone for Group 1) treatment. Ear punches (6 mm in diameter) 
were taken immediately, weighed, frozen and stored at -80 °C. 
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Ear tissues were homogenized in a phosphate buffer solution containing 0.4 M 
NaCl, 0.05% Tween-20, 0.5% BSA, 0.1 mM benzethonium, and 1% protease inhibitor 
cocktail (Boston Bioproducts). The homogenates were centrifuged at 12,000g for 30 min 
at 0°C. The supernatant fraction was used for determination of cytokine, IL-1β, IL-6 and 
TNF-α protein levels by ELISA kits, according to the manufacturer's instructions (R&D 
Systems). 
Ear tissues were homogenized in RIPA lysis buffer containing 1% protease 
inhibitor cocktail. The homogenates were centrifuged at 12,000g for 20 min at 0°C. The 
supernatant fraction was subjected to immunoblot analysis as previously described in 
Materials and methods 2.4. Antibodies for iNOS, COX-2, PI3K, p-Akt, Akt, p-ERK, 
ERK and HO-1 were obtained from Cell Signaling Technology (Beverly, MA, USA). p-
PI3K and NQO1 were obtained from Santa Cruz (Santa Cruz, CA, USA). Anti β-actin 
antibody was from Sigma-Aldrich. 
 
4.2.7 Statistical analysis 
Data are presented as means ± SD for the indicated number of independently 
performed experiments. Student's t-test was used to assess the mean difference between 
two groups. A p-value <0.05 was considered statistically significant.  
 
4.3 Results  
4.3.1 Inhibition of LPS-induced production of NO, PGE2, IL-1β and IL-6 by 4DN 
To investigate the anti-inflammatory effect of 4DN in LPS-stimulated 
macrophage cells, we firstly established nontoxic dose range of 4DN in RAW 264.7 cells. 
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As shown in Figure 4.2A, 4DN at up to 50 µM showed no effects on the viability of 
RAW 264.7 cells. Using the nontoxic dose range established, we further examined the 
effects of 4DN on LPS-induced production of inflammation mediators, namely NO, 
PGE2, IL-1β and IL-6. As shown in Figure 4.2B, the production of NO was significantly 
increased by LPS (1 µg/mL) treatment by 12.1-fold in macrophages. Treatment with 4DN 
dose-dependently inhibited LPS-induced NO production by 90-100%, at a dose range of 
10 - 50 µM. Furthermore, we determined the effects of 4DN on LPS-induced production 
of PGE2, IL-1β and IL-6 by using ELISA assay. The LPS treatment resulted in significant 
increases in the concentration of PGE2, IL-1β and IL-6 in the cell culture media (Figure 
4.2C). Treatments with 4DN at 30 µM suppressed the levels of PGE2 by 98%, as 
compared to the LPS-treated positive control cells.  Similarly, treatments with 4DN at 30 











Figure 4.2 (A) Cytotoxicity profile of 4DN in RAW 264.7 macrophages. Macrophages 
were seeded in 96-well plates. After 24 hours, cells were treated with serial 
concentrations of 4DN.  After another 24 hours of incubation, cells were subject to MTT 
assay for viability. The viability of control cells was set as the reference with a value of 
100%. Results were presented as mean ± SD from six replicates (n = 6). No significant 
difference was found between any treatment and the control group. 
(B) Effects of 4DN on LPS-induced NO production in RAW 264.7 macrophages. The 
cells were treated with LPS (positive control) or LPS plus serial concentrations of 4DN as 
indicated in the bar graph. After 24 hours of incubation, the culture media were collected 
to determine the levels of NO as described in the Method section. Results were presented 
as mean ± SD from six replicates (n = 6). All treatments showed statistical significance in 
comparison with the LPS-treated positive control. *p < 0.05, **p < 0.01, and ***p < 
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0.001 indicate statistically significant differences from the LPS-treated positive control 
group. 
(C) Effects of 4DN on LPS-induced production of PGE2, IL-1β and IL-6 in RAW 264.7 
macrophages. The cells were treated with LPS or LPS plus 4DN at concentrations 
indicated in the figure. After 24 hours of incubation, the culture media were collected and 
analyzed for protein levels of PGE2, IL-1β and IL-6 by ELISA. Results were presented as 
mean ± SD from six replicates (n = 6). *p < 0.05, **p < 0.01, and ***p < 0.001 indicate 






4.3.2 Inhibition of LPS-induced iNOS and COX-2 gene expression by 4DN 
To investigate the molecular mechanism by which 4DN inhibits the production of 
aforementioned inflammation mediators, we next determined the effects of 4DN on the 
protein levels of iNOS and COX-2 by immunoblotting analysis. We found that 4DN at 10 
and 30 µM significantly decreased protein levels of iNOS by 69 and 88%, respectively, 
when compared with LPS-treated positive control (Figure 4.3A). Similarly, 4DN at 10 
and 30 µM suppressed the protein levels of COX-2 by 54% and 91%, respectively. We 
further examined the mRNA levels of iNOS and COX-2 using qRT-PCR technique. As 
shown in Figure 4.3B, RAW 264.7 macrophages expressed very low levels of iNOS and 
COX-2 mRNA without LPS stimulation.  After 24 hours of LPS treatment, the mRNA 
levels of iNOS and COX-2 significantly elevated by 408- and 153-fold, respectively, 
which is in accordance with the protein levels of iNOS and COX-2 shown in Figure 4.3A. 
The results further showed that 4DN significantly reduced the mRNA levels of both 
iNOS and COX-2 in a dose-dependent manner. Treatments with 4DN at 30 µM resulted 
in a decrease on mRNA levels of iNOS by 83%. Similarly, 4DN at 30 µM suppressed 
mRNA level of COX-2 by 81%. The effects of 4DN on the gene expression levels of 






Figure 4.3 Inhibitory effects of 4DN on LPS-induced protein and gene expression of 
iNOS and COX-2 in RAW 264.7 macrophages. (A) The cells were seeded in 10-cm 
dishes for 24 h, and then treated with LPS or LPS plus 4DN at concentrations indicated in 
the figure. After 24 hours of incubation, cells were harvested for immunblotting as 
described in Methods. The numbers underneath of the blots represent band intensity 
(normalized to β-actin, means of 3 independent experiments) measured by Image J 
software. The standard deviations (all within ±15% of the means) were not shown. β-
Actin was served as an equal loading control. *indicates statistical significant difference 
compared to the LPS-treated positive control group (p < 0.05, n = 3). (B) The cells were 
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treated with LPS or LPS plus 4DN at concentrations indicated in the figure. After 24 
hours of incubation, total RNA was subjected to quantitative real-time RT-PCR as 
described in Methods section. The RT products were labeled with SYBR Green dye. 
Relative iNOS and COX-2 mRNA expression (2-∆∆Ct) was determined by real-time PCR 
and calculated by the Ct value for iNOS and COX-2 from GAPDH mRNA. ∆∆Ct=(Ct 
target gene-Ct GAPDH) –(Ct control-Ct GAPDH). Each value represents the mean ± SD of three 
independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 indicate statistically 





4.3.3 Inhibition on the activation of NF-κB by 4DN 
Activation and nuclear translocation of NF-κB plays central roles in mediating 
inflammation, and it is involved in regulation of iNOS and COX-2 gene expression. 
Since 4DN can inhibit iNOS and COX-2 on transcriptional levels, we next 
investigated the inhibitory effect of 4DN on the activation and nuclear/cytosolic levels of 
p65 and p50, the functional subunits of NF-κB. As shown in Figure 4.4A, we found that 
LPS treatment caused nuclear translocation of both p65 and p50, as evidenced by the 
increased nuclear accumulation of p65 and p50, and their decreased cytosolic levels after 
LPS stimulation. Treatments with 4DN significantly and dose-dependently inhibited 
LPS-induced nuclear translocation of both p65 and p50, which was evidenced by lower 
nuclear levels of p65 and p50, and higher cytosolic levels of p65 and p50 (Figure 4.4A) 
in comparison with those found in LPS-treated positive control cells. In the unstimulated 
state, NF-κB binds to IκBα, which sequesters NF-κB in an inactive cytoplasmic complex 
(24). Upon stimulation, phosphorylation of IκBα can occur, which results in dissociation 
of IκBα from NF-κB, and activated NF-κB can then be translocated into the nucleus 
where it acts as a transcription factor to initiate pro-inflammatory responses. We 
examined the expression and phosphorylation levels of IκBα protein and found that LPS 
treatment significantly increased phosphorylation of IκBα (Figure 4.4B). Treatments with 
4DN dose-dependently suppressed the phosphorylation levels of IκBα. Treatments with 





Figure 4.4 Inhibitory effects of 4DN on LPS-induced NF-κB activation in RAW 264.7 
macrophages. The cells were seeded in 10-cm dishes for 24 hours, and then treated with 
LPS or LPS plus 4DN at concentrations indicated in the figure. After 24 hours of 
incubation, cytoplasmic and nuclear fractions were prepared for immunblotting as 
described in Methods. The numbers underneath of the blots represent band intensity that 
was normalized to PARP (nuclear fraction) or β-actin (cytosolic fraction) and measured 
by Image J software (means of three independent experiments). The standard deviations 
(all within ±15% of the means) were not shown. PARP and β-Actin were served as an 
equal loading control for nuclear fraction and cytosolic fraction, respectively. *indicates 





4.3.4 Inhibition on the activation of AP-1, JNK, PI3K and Akt by 4DN 
Besides NF-κB, AP-1 is another critical transcription factor whose activation is 
involved in the pro-inflammatory responses (27). We examined the effects of 4DN on the 
levels of c-Jun and c-Fos, the key components of AP-1 protein complex. As shown in 
Figure 4.5, LPS treatment increased nuclear levels of c-Jun and c-Fos, indicating nuclear 
accumulation of AP-1 and hence its activation. LPS treatment also increased the cytosolic 
level of c-Jun, but not that of c-Fos. Treatments with 4DN dose-dependently decreased 
nuclear levels of c-Jun and c-Fos, as well as cytosolic levels of c-Jun and c-Fos.  
The activation of JNK MAP kinase was found to be involved in the upregulation 
of iNOS and COX-2 gene expression(95). Since phosphorylation is essential in the 
activation of JNK, we examined the effect of 4DN on the phosphorylation of JNK. As 
shown in Figure 4.6, LPS treatment showed marginal effects on the phosphorylation of 
JNK, and 4DN at 30 µM significantly decreased phosphorylation of JNK. PI3K/Akt 
pathway is another signaling pathway whose activation has been found to be associated 
with pro-inflammatory effects such as up-regulation of the transcriptional activity of NF-
κB (96). We examined the phosphorylation levels of PI3K and Akt. The results showed 
that 4DN showed moderate inhibitory effects on the phosphorylation of PI3K, but had 
potent inhibitory effects on the phosphorylation of Akt. For example, 4DN at 30 µM 
decreased the phosphorylation level of Akt by 90%. 4DN treatments had no effects on the 





Figure 4.5 Inhibitory effects of 4DN on LPS-induced AP-1 activation in RAW 264.7 
macrophages. The cells were seeded in 10-cm dishes for 24 h, and then treated with 1 
µg/mL of LPS or LPS plus 4DN at concentrations indicated in the figure. After 24 hours 
of incubation, cytoplasmic and nuclear fractions were prepared for immunoblotting as 
described in Methods. The numbers underneath of the blots represent band intensity that 
was normalized to PARP (nuclear fraction) or β-actin (cytosolic fraction) and measured 
by Image J software (means of three independent experiments). The standard deviations 
(all within ±15% of the means) were not shown. PARP and β-Actin were served as an 
equal loading control for nuclear fraction and cytosolic fraction, respectively. *indicates 






Figure 4.6 Inhibitory effects of 4DN on phosphorylation of PI3K, Akt and JNK in RAW 
264.7 macrophages. The cells were seeded in 10-cm dishes for 24 hours, and then treated 
with LPS or LPS plus 4DN at concentrations indicated in the figure. After 24 hours of 
incubation, cells were prepared for immunoblotting as described in Methods. The 
numbers underneath of the blots represent band intensity that was normalized β-actin and 
measured by Image J software (means of three independent experiments). The standard 
deviations (all within ±15% of the means) were not shown. β-Actin were served as an 
equal loading control. *indicates statistical significance from the LPS-treated group (p < 




4.3.5 Induction of anti-oxidative enzymes by 4DN 
HO-1 and NQO1 are anti-oxidative enzymes that are associated with anti-
inflammatory effects (53, 97). We determined the effect of 4DN on the protein and gene 
expression of HO-1 and NQO1. As shown in Figure 4.7A, treatments with 4DN at 10 and 
30 µM significantly increased the protein levels of HO-1 by 2.0 and 2.12-folds, 
respectively, when compared with LPS-treated positive control cells. Similarly, the 
protein levels of NQO1 were also increased by 4DN treatment as compared to the LPS-
treated positive control group. Next, we analyzed the mRNA levels of HO-1 and NQO1 
using qRT-PCR technique (Figure 4.7B). It was found that 4DN treatments does-
dependently and significantly elevated the mRNA expressions of HO-1 and NQO1, 
which is in accordance with the effects of 4DN on the protein levels of HO-1 and NQO1. 
Treatment with 4DN at 30 µM resulted in an increase on mRNA level of HO-1 by 72% in 
comparison with the LPS-treated positive control cells. Treatments with 4DN at 30 µM 
enhanced mRNA level of NQO1 by 76%, compared to the LPS-treated positive control 
cells. The results demonstrated that 4DN treatment induced gene and protein expression 
of HO-1 and NQO1. 
Previous reports showed that the transcription factor Nrf2 mediates the 
transcriptional activation of many anti-oxidative genes. For example, activation and 
nuclear translocation of Nrf2 plays a key role in the induction of HO-1 and NQO1 (28, 
30). To elucidate the mechanisms underlying the induction of HO-1 and NQO1 elicited 
by 4DN, we determined the effects of 4DN on the protein levels Nrf2. The protein levels 
of Nrf2 in nuclear and cytosolic fractions were determined after treatment with 4DN by 
immunoblotting analysis. As shown in Figure 4.7C, 4DN significantly enhanced the 
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protein level of Nrf2 in nuclear fraction in comparison with LPS-treated positive control 
cells, and these effects were in a dose-dependent fashion. Meanwhile, the protein level of 
Nrf2 in cytosolic fraction was decreased by 4DN treatment. The results suggested that 
4DN treatment resulted in nuclear translocation of Nrf2, which in turn induced 






Figure 4.7 Effects of 4DN on protein and gene expression of anti-oxidative enzymes 
HO-1 and NQO1 in LPS-stimulated RAW 264.7 macrophages. The cells were seeded in 
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10-cm dishes for 24 hours, and then treated with LPS or LPS plus 4DN at concentrations 
indicated in the figure. After 24 h of incubation, cells were harvested for western 
immunoblotting as described in Methods. The numbers underneath of the blots represent 
band intensity (normalized to β-actin, means of 3 independent experiments) measured by 
Image J software. The standard deviations (all within ±15% of the means) were not 
shown. β-Actin was served as an equal loading control. *indicates statistical significance 
from the LPS-treated positive control group (p < 0.05, n = 3). (B) The cells were treated 
with LPS or LPS plus 4DN at concentrations indicated in the figure. After 24 h of 
incubation, total RNA was subjected to quantitative real-time RT-PCR. Relative HO-1 
and NQO1 mRNA expression (2-∆∆Ct) was determined by real-time PCR and calculated 
by the Ct value for HO-1 and NQO1 from GAPDH mRNA. Each value represents the 
mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 
indicate statistically significant differences from the LPS-treated positive control group.!
(C) Effects of 4DN on nucler translocation of Nrf2 in RAW 264.7 macrophages. The 
cells were seeded in 10-cm dishes for 24 h, and then treated with LPS or LPS plus 4DN 
at concentrations indicated in the figure. After 24 hours of incubation, cytoplasmic and 
nuclear fractions were prepared for western immunoblotting as described in Methods. 
The numbers underneath of the blots represent band intensity (normalized to PARP or β-
actin, means of three independent experiments) measured by Image J software. The 
standard deviations (all within ±15% of the means) were not shown. PARP and β-Actin 
were served as an equal loading control. *indicates statistical significance from the LPS-




4.3.6 Inhibitory effect of NBT and 4DN on TPA-induced edema in mouse ears 
We utilized a TPA-induced ear edema mouse model to investigate the in vivo 
anti-inflammatory activities of 4DN. It is a well-established model that has been used to 
evaluate the protective effects of dietary compounds against skin inflammation, such as 
wogonin, black tea theaflavin derivatives and Polygonum cuspidatum extract(98-100). 
Average weight of ear!punches is an important indicator of inflammation in ears that 
reflects the degree of skin edema. As shown in Figure 4.8, topical application of TPA (2 
nmol) for 6 h significantly increased the weight of mouse ear to 173.4%, compared to the 
vehicle-treated control group. Topical application of 2 and 4 µmol of NBT 30 min before 
TPA treatment modestly inhibited TPA-induced ear edema by 29.6 and 44.8%, 
respectively, compared to the TPA group. However, 2 and 4 µmol of 4DN significantly 
decreased TPA-induced ear edema by 69.0 and 88.2%, respectively, in a dose-dependent 
manner. These results suggested that 4DN had much stronger protective effects against 





Figure 4.8 Inhibitory effects of topical application NBT and 4DN on TPA-induced 
edema of mouse ears. Both ears of male CD-1 mice (n = 6) were topically treated with 10 
µL of acetone (vehicle control) or NBT/4DN (2 µmol or 4 µmol) in 10µL of acetone 30 
min prior to application of acetone or 2 nmol TPA in acetone. The mice were sacrificed 6 
h after TPA treatment. Ear punches (6 mm in diameter) were taken immediately and 
weighed. Data are shown as mean ± SE. Different notations in the bar charts indicate 





4.3.7 Inhibitory effect of 4DN on TPA-induced up-regulation of pro-inflammatory 
cytokines in mouse ears 
To investigate the molecular mechanisms by which 4DN suppressed TPA-
induced skin inflammation, we next determine the effects of 4DN on the expression 
levels of pro-inflammatory cytokines in mouse ears by ELISA. As shown in Figure 4.9, 
topical treatment of TPA for 6 h dramatically elevated the expression levels of pro-
inflammatory cytokines IL-1β, IL-6 and TNF-α in mouse ears. The up-expression of pro-
inflammatory cytokines was consistent with the skin inflammation (ear thickness) in 
mouse ears. In comparison with the control group, TPA treatment caused 6.6-, 13.0- and 
3.1-fold increase of protein levels of IL-1β, IL-6 and TNF-α, respectively. However, 
topical application of 2 and 4 µmol of 4DN to ears 30 min before TPA treatment 
effectively and does-dependently reduced TPA-induced up-regulation of IL-1β, IL-6 and 
TNF-α. 2 and 4 µmol of 4DN retarded TPA-induced overexpression of IL-1β by 63.5 and 
77.2%, compared to the TPA group, respectively. For IL-6, 2 and 4 µmol of 4DN greatly 
reduced that by 84.1 and 84.8%, compared to the TPA group, respectively. For TNF-α, 2 
and 4 µmol of 4DN also significantly decreased that by 37.0 and 31.6%, respectively. 
Together, these results indicated that 4DN markedly suppressed TPA-induced 
overexpression of pro-inflammatory cytokines in mouse ears. This finding accorded with 





Figure 4.9 Effects of 4DN treatment on protein levels of IL-1β, IL-6 and TNF-α in ears 
of the CD-1 mouse. Half of the ears in same group (6 mice per group) were pooled for 
ELISA analysis as descried. Data are shown as the mean ± SD of three independent 
experiments. Data are shown as mean ± SD. Different notations in the bar charts indicate 






4.3.8 4DN profoundly modulated key proteins related to inflammation and cell 
proliferation in TPA-treated mice 
To further investigate the molecular mechanisms underlying the in vivo anti-
inflammatory of 4DN, we utilized western blotting to analyzed the effect of 4DN on 
multiple proteins related with inflammatory pathways in TPA-treated mice, including 
iNOS, COX-2 and matrix metalloproteinase-9 (MMP-9). In inflammatory cells, iNOS 
and COX-2 are two key pro-inflammatory enzymes that can stimulate the expression of 
critical inflammatory mediators NO and PGE2, respectively(26). TPA has been 
demonstrated as a promoter of skin inflammation and tumorigenesis, and stimulated the 
expression of many inflammation and cancer related proteins(96, 102). The MMP-9 
protein is an important matrix metalloproteinase enzyme that plays a critical role in tumor 
invasion and metastasis, and it has been reported to be overexpressed in many human 
cancers(103). MMP-9 is also associated with pathological process of many inflammation 
related diseases, such as rheumatoid arthritis and osteoarthritis(54). As shown in Figure 
4.10, topical application of TPA for 6 h caused a dramatic increase in the protein levels of 
iNOS (3.7-fold), COX-2 (6.2-fold) and MMP-9 (13.3-fold) in mouse ears, compared to 
the control group. In contrast, topical application of 4 µmol of 4DN 30 min prior to TPA 
application resulted in great reduction in the protein levels of iNOS, COX-2 and MMP-9 
by 54, 66 and 69%, respectively, as compared to TPA-treated group.  
Recently, nuclear factor erythroid 2-related factor 2 (Nrf2) and its target genes 
HO-1 and NQO1 has been demonstrated to play the inhibitory roles in TPA-treated 
mouse skin epidermal JB6 cells(104). Since 4DN resulted in induction of Nrf2 pathway 
in RAW 264.7 cells(101), we next investigated whether 4DN exerts any interferes with 
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HO-1 and NQO1 expression in TPA-treated mouse ears. As shown in Figure 4.10, topical 
application of 4DN 30 min prior to TPA application significantly increased the 
expression levels of NQO1 in a dose-dependent manner. For HO-1, 4 µmol 4DN showed 
a modest enhancement, while at 2 µmol did not cause significant change. 2 and 4 µmol of 
4DN increased NQO1 expression by 1.8- and 2.3-fold compared the TPA group, 
respectively. These results suggested that the anti-inflammatory effect of 4DN against 
TPA-induced ear edema involved the induction of phase II enzymes. These results were 
consistent with our previous finding on RAW 264.7 cells(101). 
The activation of phosphoinositide 3-kinase (PI3K)/Akt and extracellular signal-
regulated kinase (ERK) MAP kinase pathways plays important roles in inflammatory 
response. The phosphorylation of PI3K/Akt and ERK has found to be involved in the 
activation and nuclear translocation of eukaryotic transcription factor nuclear factor-
kappa B (NF-κB) and the expression of NF-κB downstream target genes, such as iNOS 
and COX-2(96, 105, 106). As shown in Figure 4.10, TPA treatment induced the 
phosphorylation of PI3K (4.9-fold), Akt (8.1-fold) and ERK (2.9-fold), as compared to 
the vehicle control group. In contrast, topical application of 4DN 30 min prior to TPA 
application resulted in significant inhibition of the expression of phosphorylated PI3K, 
Akt and ERK. For example, 4 µmol 4DN significantly reduced phosphorylated PI3K and 
Akt by 67 and 53%, respectively, in comparison to TPA-treated group. And 2 µmol 4DN 
decreased phosphorylated ERK by 45%. Although 4 µmol of 4DN showed less inhibitory 
effects on the phosphorylation levels of ERK than that produced by 2 µmol of 4DN, both 
concentrations did significantly reduce the activation of ERK in TPA-treated mouse ears. 
!
91!
Meanwhile, only modest change was observed in the total content of PI3K, Akt and ERK 








Figure 4.10 Effects of 4DN on key proteins related to inflammation and cell proliferation 
in TPA-treated CD-1 mouse. Half of the ears in same group (6 mice per group) were 
pooled for western blot analysis as descried. Data are shown as the mean ± SD of three 
independent experiments. The numbers underneath of the blots represent band intensity 
(normalized to β-actin, means of three independent experiments) measured by Image J 
software.!The SDs (all within ±15% of the means) were not shown. β-Actin was served as 
an equal loading control. * indicates statistical significance in comparison with the 







Biotransformation is critical factor that may profoundly influence the biological 
effects of orally ingested bioactive compounds such as nutraceuticals (21). Many 
nutraceuticals undergo extensive metabolism in the gastrointestinal tract and the liver to 
be transformed to various metabolites. These metabolites may elicit significant biological 
effects depending on their chemical structures and abundance in the specific tissues. As a 
major polymethoxyflavone found in citrus fruits, nobiletin has been shown to have 
various beneficial health effects. Several metabolites of nobiletin have been identified in 
in vivo studies (44, 46, 47, 94). Our recent study revealed that 4DN was the most 
abundant colonic metabolite of nobiletin after long-term dietary administration of 
nobiletin in mice (47). Furthermore, it is noteworthy that the level of 4DN in the colonic 
mucosa was about 12-fold higher that that of nobiletin (47). These findings suggested that 
due to its high abundance, 4DN might play important roles in the biological effects 
elicited by dietary treatment with nobiletin. Inflammation is associated with multiple 
diseases, and anti-inflammation is considered as a promising strategy to the prevention of 
inflammation-driven diseases. Therefore, it is meaningful to determine the anti-
inflammatory effects of 4DN. The main objective of this study is to establish the 
inhibitory effects of 4DN on LPS-induced inflammation and elucidate the underlying 
molecular mechanisms.  
Our results demonstrated that 4DN (at 10 and 30 µM) effectively suppressed LPS-
induced inflammation by down-regulating iNOS, COX-2, PGE2, IL-1β and IL-6, 
inhibiting the activation of NF-κB, AP-1, JNK MAP kinase, and PI3K/Akt pathways, and 
up-regulating Nrf2-regulated anti-oxidative genes such as NQO-1 and HO-1. These 
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findings are physiologically relevant to the in vivo situation because 10 and 30 µM of 
4DN are achievable in animal tissues after oral administration of nobiletin. This was 
based on our previous finding that long term (20 weeks) feeding of mice with nobiletin 
(500 ppm in diet) resulted in 20-30 µM of 4DN in the colonic mucosa (47). Inflammation 
plays important roles in promoting colon carcinogenesis, and previous studies have 
showed that dietary administration of nobiletin suppressed colon carcinogenesis in rodent 
(14-16). Therefore, based on our results, it is reasonable to argue that 4DN as a major 
colonic metabolite of nobiletin may significantly contributed to the anti-colon 
carcinogenesis effects of nobiletin by eliciting anti-inflammatory effects in the colon.  
Inflammation plays important roles in promoting colon carcinogenesis, and 
previous studies have showed that dietary administration of nobiletin suppressed colon 
carcinogenesis in rodent (14-16). Therefore, based on our results, it is reasonable to argue 
that 4DN as a major colonic metabolite of nobiletin may significantly contributed to the 
anti-colon carcinogenesis effects of nobiletin by eliciting anti-inflammatory effects in the 
colon.  
As NF-κB and AP-1 are critical transcription factors that regulate inflammatory 
pathways (24, 27), we determined the effects of 4DN on those transcription factors in 
LPS-stimulated macrophage cells. Nuclear translocation of NF-κB is known to play a 
crucial role in the regulation of genes coding many pro-inflammatory enzymes and 
cytokines, including iNOS and COX-2 (26). Our results showed that LPS caused 
increased level of phosphorylation of IκBα, which led to dissociation of IκBα from NF-
κB in the cytosol. Freed NF-κB can then be translocated to nucleus and elicit its 
transcriptional activity. Treatment of 4DN effectively inhibited LPS-induced 
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phosphorylation of IκBα, which increased anchorage of NF-κB in the cytosol. This in 
turn deceased nuclear translocation of NF-κB. Nuclear translocation of AP-1, induced by 
a number of stimuli, including cytokines, growth factors and infections, is also crucial in 
regulating the induction of iNOS and COX-2 (27). Our results indicated that 4DN dose-
dependently inhibited LPS-induced nuclear translocation of key subunits of AP-1, 
namely c-Jun and c-Fos. Interestingly, the cytosolic levels of c-Jun and c-Fos were also 
significantly decreased by 4DN treatments. This result suggested that in addition to the 
inhibition on nuclear translocation of AP-1, 4DN might also promote degradation of AP-
1 subunits in the cytosol. The inhibitory effects of 4DN on NF-κB and AP-1 were 
consistent with the inhibitory effect of 4DN on the gene transcription of iNOS and COX-
2. Furthermore, the activation of NF-κB and AP-1 has been proposed to be mediated by 
many signaling pathways, including PI3K/Akt and JNK pathways (25, 95, 107).!Our 
results demonstrated that 4DN suppressed phosphorylation levels of JNK, PI3K and Akt. 
Taken together, our results suggest that 4DN exerts its anti-inflammatory effects by 
suppressing NF-κB and AP-1 dependent pro-inflammatory gene expression.  
A growing number of studies have demonstrated that increased levels of anti-
oxidative enzymes, such as HO-1 and NQO1, play important roles in inhibiting LPS-
induced inflammation in RAW 264.7 cells (53, 97). HO-1 can promote the production of 
antioxidants such as bilirubin and carbon monoxide (CO); further leads to decreased 
iNOS and COX-2 enzymatic activities (108, 109). Overexpression of NQO1 has been 
shown to inhibit LPS-induced TNF and IL-1β expression through an NF-κB-independent 
pathway (110). Nrf2 is a key transcription factor that mediates the gene expression of a 
number of enzymes, including HO-1, NQO1, Glutamate-cysteine ligase, catalytic (Gclc), 
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glutamate-cysteine ligase, modifier (GCLM) and glutathione S-transferase (GST) family. 
It has been reported that activation and nuclear translocation of Nrf2 can protect 
abnormal inflammatory response by inducing cellular rescue pathways and relieve 
adverse effects of LPS-induced NF-κB activity (28, 29). Furthermore, Nrf2 has been 
shown to be protective against various inflammatory diseases, such as acute lung 
inflammation (97), colorectal cancer (111), cardiovascular disease (112) and diabetic 
retinopathy (113). Therefore, modification of Nrf2 activity has been considered as a 
rational approach for chemoprevention of inflammation-driven diseases.!Our results 
demonstrated that 4DN dose-dependently increased nuclear translocation of Nrf2, which 
in turn led to increased expression of HO-1 and NQO1 at both mRNA and protein levels. 
These findings suggested that induction of HO-1 and NQO1 via the activation of Nrf2 
contributed to the inhibitory effect of 4DN on LPS-induced inflammation in RAW 264.7 
macrophages.  
In our in vivo study, 4DN showed strong anti-inflammatory effects on TPA-
treated mice. Ear thickening within a short span of time (1-24 h) caused by edema, 
elevated vascular permeability and dermis!swelling is a common hallmark of irritation 
and local inflammatory response in skin in the TPA model. It is a well-established acute 
skin inflammation model that is useful for evaluating prospective anti-inflammatory 
agents in vivo (98-100, 114). Topical application of TPA to mouse ears strongly induced 
thickening and edema of ear skin, as well as up-expression of key pro-inflammatory 
biomarkers, such as PGE2, IL-6, IL-1β, TNF-α, intercellular adhesion molecule (ICAM)-
1 and COX-2(98, 100). We found the in vitro anti-inflammatory effects of 4DN in mouse 
macrophage cell. These effects were associated with inhibition of PGE2, IL-6, IL-1β and 
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COX-2 signaling pathways(101). Therefore, TPA-induced acute skin inflammation 
mouse model is an ideal animal model for us to further investigate the in vivo anti-
inflammatory properties of 4DN. We first evaluated and compared the in vivo anti-
inflammatory effects of NBT and 4DN by using this TPA model. We observed that 4DN 
had much stronger inhibitory effects against TPA-induced ear edema (thickening). 4 
µmol of NBT only showed 44.8% inhibition, compared to TPA group, whereas 4 µmol of 
4DN showed about 88.2% inhibition. Previously, Li et al. reported that 4DN had more 
potent anti-inflammatory than NBT in RAW264.7 macrophages(45). Our results 
reinforced that 4DN as a major metabolite of NBT, may play a more important role in the 
anti-inflammatory effects of orally administered NBT. 
Next, we investigated the mechanism of action of 4DN by using ELISA and 
western blotting. 4DN treatments exerted great inhibitory effects against ear edema, 
overexpression of NO, IL-1β, IL-6 and TNF-α in TPA-stimulated mice. In addition, our 
results demonstrated that decreased levels of iNOS, COX-2, MMP-9, phosphorylated 
PI3K/Akt/ERK and increased levels of phase II enzyme HO-1 and NQO1 by 4DN 
treatments were!attributable to the its protective effects against TPA treatment. These 
findings are consistent with our in vitro study, suggesting that 4DN is a promising 
bioactive component that deserves!further investigation in other inflammation-related 
carcinogenesis models. 
In summary, we observed that 4DN, a major metabolite of nobiletin, significantly 
inhibited LPS-stimulated gene expression of iNOS and COX-2 in RAW 264.7 
macrophages. These effects were associated with suppressing the degradation and 
phosphorylation of IκB, translocation of NF-κB and AP-1 transcription factors and 
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activation of JNK MAPK and PI3K/Akt signaling pathways. Furthermore, for the first 
time, we demonstrated that the metabolite of nobiletin was able to elevate the gene 
expression of phase II enzyme HO-1 and NQO1 by enhancing the translocation of Nrf2. 
In addition, we found that 4DN produced strong protective effects against TPA-induced 
skin inflammation in mouse ears via inhibition of iNOS, COX-2, PI3K/Akt, ERK 
pathways, as well as induction of antioxidant enzymes HO-1 and NQO1. Overall, our 
results demonstrated that 4DN had strong anti-inflammatory effects both in vitro and in 
vivo, which provided a solid scientific basis for using nobiletin to inhibit inflammation 





SYNERGISTIC CHEMOPREVENTIVE EFFECTS OF NOBILETIN (NBT) AND 
ATORVASTATIN (ATST) ON COLON CARCINOGENESIS 
5.1 Introduction 
A growing body of evidence suggests that combination of cancer 
chemopreventive agents may produce enhanced protective effects against carcinogenesis 
than each individual agent alone. The enhanced efficacy by the combination can also 
decrease the required dosage for each single agent in the combination, which in turn may 
reduce the potential toxicity and/or side effects from high-dose administration (115). As a 
cancer of high incidence, colon cancer has been frequently investigated as an important 
target of combination regimen. Accumulating studies suggest that dietary bioactive 
components in combination may synergistically enhance the chemopreventive effects of 
individual component alone against colon carcinogenesis in the last two decades. Challa 
et al. reported that green tea and phytic acid in combination significantly decreased the 
aberrant crypt foci (ACF) incidence in azoxymethane (AOM)-treated rats (64). Xu et al. 
reported that the combination of curcumin and green tea catechins exhibited a significant 
reduction in ACF numbers, tumor incidence and cell proliferation in dimethylhydrazine-
induced rats (65). Bose et al. demonstrated that fish oil plus (−)-epigallocatechin-3-
gallate reduced the tumor occurrence, number of large tumors, levels of PGE2, nuclear β-
catenin and phosphorylated Akt in Apc Min/+ mouse model(65). Therefore, combination 
regimen is a promising strategy for colon cancer chemoprevention. 
Polymethoxyflavone (PMFs) is a unique group of bioactive flavonoids found 
almost exclusively in sweet oranges (Citrus sinensis) and mandarin oranges (Citrus 
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reticulate), particularly in their peels(57).!There have been more than 20 PMFs being 
isolated and identified from citrus fruits, such as sinensetin (5,6,7,3',4'-
pentamethoxyflavone), nobiletin (5,6,7,8,3',4'-hexamethoxyflavone, NBT), and tangeretin 
(5,6,7,8,4'-pentamethoxyflavone). PMFs are the secondary compounds located in the peel, 
especially in the flavedo that act as antifungal agents (37). We and others have 
demonstrated a wide range of biological activities of PMFs, such as anti-inflammatory(10, 
53, 101), anti-carcinogenic(18, 46, 58, 116), and anti-adipogenic(51) activities. In 
particular, NBT, one major PMF, has been shown to inhibit colon carcinogenesis in 
different cell culture and animal models. Morley et al. reported that NBT inhibited HT-29 
human colon cancer cell proliferation by inducing G1 cell cycle arrest(117). Suzuki et al. 
found that NBT inhibited AOM-induced colon carcinogenesis in rats, as well as increased 
apoptotic activities and decreased prostaglandin E2 content (14). Wu et al. demonstrated 
that NBT inhibited AOM/!dextran sulfate sodium (DSS)-induced colitis associated colon 
carcinogenesis in mice, and this protective effect was related to its colonic 
metabolites(116). Together, these studies suggested that NBT had strong anti colon 
cancer activities both in vitro and in vivo. 
Atorvastatin (ATST, commercially sold as Lipitor®!or Torvast®) is a member of 
statins family, which is a drug class used mainly for lowering blood cholesterol and for 
prevention of cardiovascular disease. Statins work in the mevalonate pathway by 
inhibiting 3-hydroxy-3-methyl-glutaryl CoA reductase (HMG-CoA reductase); a rate-
limiting enzyme found in liver that plays critical role in cholesterol biosynthesis in the 
body(66).!Lipitor® became the top selling statin for more than one decades. Nowadays, it 
is still a widely prescribed cholesterol-lowering medicine. Besides its lipid-lowering 
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effect, observational, preclinical and clinical studies have suggested that ATST might 
help prevent colon carcinogenesis in human(66, 72).!Furthermore, in the past decade, 
accumulating studies have shown that combination of ATST with other dietary agents 
and/or drugs can exert enhanced anti-cancer efficacy both in vitro and in vivo against 
various cancers, including colon(72, 73), lung(74, 75) and prostate cancer(76, 77). Xiao 
et al. reported that combination of ATST and celecoxib (a COX-2 selective NSAID) 
synergistically inhibited the growth of HT-29 and HCT116 human colon cancer cells via 
inducing G0/G1 cell cycle arrest and apoptosis, and modulating the membrane 
localization of small G-proteins (72). Lu et al. investigated the possible synergistic 
inhibitory effects of ATST plus green tea polyphenols in H1299 and H460 lung cancer 
cells and a mouse lung tumorigenesis model. They found that the individual agents did 
not show significant anti-carcinogenic activities in animal model, however, low-dose co-
treaments of ATST/green tea polyphenols effectively reduced the tumor multiplicity and 
tumor burden (74). Zheng et al. reported that ATST and celecoxib in combination at 
lower dose than each individual agent alone exhibited a more potent efficacy in inhibiting 
the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen 
independence(76). 
Our group is foucsed on the development of colon cancer preventive strategy 
utilizing bioactive PMFs from citrus peels. However, whether the combination of NBT 
and ATST can inhibit colon carcinogenesis has never been reported. Herein, for the first 
time, we investigated the potential protective effects of the combination of NBT with 




5.2 Materials and methods 
5.2.1 Cell cultures and treatments 
Human colorectal cancer cell line HT-29 was obtained from American Type Cell 
Collection (ATCC, Manassas, VA, USA). HT-29 cells were maintained in RPMI 1640 
media (Mediatech, Herndon, VA, USA) supplemented with 5% heat-inactivated fetal 
bovine serum and 100 U/mL of penicillin and 0.1 mg/mL of streptomycin at 37°C with 5% 
CO2 and 95% air. Cells were kept subconfluent and media were changed every 3–4 days. 
All cells used in experiments were between 4 and 25 passages. Nobiletin (NBT) and 
atorvastatin (ATST) were purchased from Bepharm Ltd. (Shanghai, China). 
Dimethylsulfoxide (DMSO) was used as vehicle to deliver NBT and ATST to the cells. 
The final concentration of DMSO in all experiments was 0.1% v/v in cell culture media. 
 
5.2.2 Cell viability assay and analyses of synergy!!
HT-29 (2,000 cells/well) cells were seeded in 96-well plates. After 24 h, cells 
were treated with serial concentrations of NBT, ATST and their half dose combinations 
in 200 µL of complete media. After 72 h, the media were replaced with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich, St. Louis, MO, 
USA)-containing medium for viability test as we previously reported(19). The analyses 
were based on Chou and talalay’s empirical method (118) with modifications as 
described previously(53, 72). The combination index was used to determine additivity, 
antagonism, and synergy of the combination treatment of NBT and ATST at different 
dose pairs depending on the combination index = 1, > 1, and < 1, respectively. The delta 
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method (119) was used to calculate the variance of the interaction index. Data were 
further analyzed by using R program software. 
 
5.2.3 Flow cytometric analysis of cell cycle distribution and apoptosis 
HT-29 (7 × 104 cells/well) cells were seeded in 6-well plates. After 24 h of 
incubation for cell attachment, cells were treated with serial concentrations of NBT, 
ATST, and their half dose co-treatment in 2 mL of serum complete media. Media 
containing any floating cells were harvested and combined with adherent cells that were 
detached by brief trypsinization (0.25% trypsin-EDTA; Mediatech). Cell pellets were 
washed with 1 mL of ice-cold PBS then subject to cell cycle and apoptosis analysis as we 
described previously(19). 
 
5.2.4 Animals, diets, experimental procedure  
The protocol for the animal experiment was approved by Institutional Animal 
Care (permission number, 2011-0066) and Use Committee of the University of 
Massachusetts Amherst. To evaluate the anti-carcinogenic effects of NBT/ATST co-
treatment, an AOM-induced rat colon carcinogenesis model is used for this study. The 
male F344 rats (5 wk of age) were obtained from Charles River Laboratories 
(Wilmington, MA, USA). Upon arrival, the rats were kept in a temperature-controlled 
animal room (23°C), humidity (65–70%) and day/night cycle (12 h light, 12 h dark) with 
free access to water and a modified 20% high-fat AIN-76A diet for 1 week for 
acclimation. Rats were then randomly divided into four groups (30 animals each). At 
week 2 and week3, F344 rats in all groups were given subcutaneous injections of AOM 
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(15 mg·kg-1) injection twice. Group 1, AOM control; Group 2, 0.1% NBT powder, NBT 
(>98%); Group 3, 0.04% ATST powder, ATST (>98%); Group 4, 0.05% NBT + 0.02% 
ATST. Treatments were administrated to rats starting one week after the second AOM 
inject for 40 weeks, continued until the end of study. Body weights, food and fluid 
consumption, and general health status will be monitored twice a week. All rats were 
sacrificed by CO2 asphyxiation at 20 weeks for evaluation of tumors in colonic tissues.!
The liver and spleen were removed and weighed.!After measurement of the length and 
weight, the entire colons were cut longitudinally, rinsed with phosphate-buffered saline 
(pH 7.4) and then macroscopically inspected. Number and size of carcinoma in the 
colons were documented using an ocular micrometer. The sizes of tumors were 
determined by the following formula: tumor volume (mm3) = L × W2 / 2, where L is the 
length and W is the width of the tumor(79). Colons were stored at -80°C for qRT-PCR 
and immunoblotting analysis. The interaction between NBT and ATST (synergistic, 
additive, or antagonistic) was analyzed based on the ‘simple designs and model-free tests 
for synergy’ by Laska et al(120).  
 
5.2.5!Real-Time qRT-PCR analysis 
Real-Time qRT-PCR analysis was conducted as previously described(53). The 
primer pairs were synthesized by Integrated DNA Technologies, Inc. (Coralville, IA, 
USA) with the following primers: IL-1 F: 5′-TGACAGACCCCAAAAGATTAAGG-3′, 
R: 5′-CTCATCTGGACAGCCCAAGTC-3′; IL-6 F: 5′-
CCCACCAGGAACGAAAGTCA-3′, R: 5′-CTTGCGGAGAGAAACTTCATAGC-3′; 
TNF-α F: 5′-ACAAGGCTGCCCCGACTAT-3′, R: 5′-
!
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CTCCTGGTATGAAGTGGCAAATC-3′; GAPDH F: 5′-
ACCACAGTCCATGCCATCAC-3′, R: 5′-TCCACCACCCTGTTGCTGTA-3′(121). A 
minimum of three independent experiments was carried out, and each experiment had 
triplicate samples for each treatment. The copy number of each transcript was calculated 
with respect to the GAPDH copy number, using the 2−ΔΔCt method(84).  
 
5.2.6 Immunoblotting 
For whole cell lysate analysis, total scraped colon mucosa was homogenized on 
ice for 15 s using a tissue homogenizer and then lysed in 1.5 mL of ice-cold lysis buffer, 
supplemented with cocktails of protease inhibitor (1:100), phosphotase inhibitor 1 
(1:100), and phosphotase inhibitor 2 (1:100), on ice for 30 min, followed by 
centrifugation at 10,000g for 30 min at 4 °C. Membrane-bound proteins were prepared by 
using Mem-PER™ Plus Membrane Protein Extraction Kit (Thermo Fisher Scientific, 
Waltham, MA)!following the manufacturer’s instruction. Proteins were quantified by 
BCA protein assay kit, and 50-100 µg of proteins were resolved by SDS-PAGE and 
transferred to nitrocellulose membrane. After blocking, proteins of interest were probed 
using different antibodies at the manufacturer's recommended concentrations and then 
visualized using Odyssey CLx infrared imaging system (LI-COR Biosciences, Lincoln, 
NE, USA). Antibodies for VEGF, EGFR, p21Cip1/Waf1, cyclin D, RhoA and β-tubulin were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies for p-EGRF, 
MMP-9, cleaved-caspase 7, cleaved-caspase 3, cleaved-PARP, p53, CDK2, CDK4 and 
cyclin E were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-β 




5.2.7 Statistical analysis 
All data were presented as mean ± SD. Student’s t-test was used to test the mean 
difference between two groups. Analysis of variance (ANOVA) model was used for the 
comparison of differences among three or more groups.  A p value <0.05 was considered 
to be statistically significant. 
 
5.3. Results  
5.3.1 NBT/ATST co-treatment showed synergistic growth inhibitory effects on 
human colon cancer cells 
We first investigated the possible synergistic interactions between NBT and 
ATST on cell proliferation inhibition in HT-29 human colon cancer cells by utilizing cell 
viability assay. To evaluate the growth inhibitory effects of NBT/ATST co-treatments, 
HT-29 cells were serial concentrations of NBT, ATST, and NBT/ATST combinations at 
a 2:1 ratio for 72 hr. As shown in Figure 5.1, NBT and ATST treatment caused a dose-
dependent growth inhibition on HT-29 cells. More importantly, we observed the half 
dose combinations of NBT and ATST (half concentration of NBT plus half concentration 
of ATST) resulted in a much stronger growth inhibitory activities on HT-29 cells than the 
individual compounds with NBT or ATST at full doses. For example, a combination of 
12 µM NBT with 6 µM ATST caused a 66% inhibition, while 24 µM NBT alone and 12 
µM ATST alone led to only 29 and 20% inhibition, respectively. Similarly, 18 µM NBT 
with 9 µM ATST caused a 94% inhibition, while 36 µM NBT alone and 18 µM ATST 
alone led to only 43 and 39% inhibition, respectively. And it is noteworthy that the 
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growth inhibitory effect of 12 µM NBT with 6 µM ATST co-treatment was also much 
stronger than that produced by 36 µM NBT alone or 18 µM ATST alone.  
As we observed significant enhanced growth inhibitory efficacy from NBT/ATST 
co-treatments, we further determined the mode of interaction between NBT and ATST 
using isobologram analysis adapted from Chou & Talalay’s empirical method(118) with 
modifications as we described previously(53, 72). As shown in Figure 5.2A, the median 
effect plot confirmed that the linear regression model used in the isobologram analysis!
was well-fitted to the dose-response relationship of NBT, ATST and their combinations 
within the concentration ranges exploited herein. Based on the median effect plot, we 
calculated the interaction index of each combination dose pair of NBT/ATST as 
described in Materials and methods. The interaction index was used to determine 
additivity, synergy, or antagonism of the combination at each combination dose pair 
depending on interaction index =1, <1, or >1, respectively. If the interaction index is 
smaller than 0.3, there is a strong synergism between two tested compounds(118). As 
shown in Figure 5.2B, all NBT/ATST combination dose pairs resulted in interaction 
indexes lower than 1, indicating synergistic interaction between NBT and ATST in terms 
of inhibiting HT-29 cell proliferation. Moreover, the interaction indexes of NBT/ATST at 
the two highest dosed pairs (12 µM NBT + 6 µM ATST, 18 µM NBT + 9 µM ATST) 
were even lower than 0.3, suggesting a strong synergism. Together, our results 
demonstrated a synergistic interaction between NBT and ATST in growth inhibition of 









Figure 5.1. (A) Chemical structures of NBT and ATST. (B) Growth inhibitory effect of 
NBT, ATST and their half dose combination on HT-29 human colon cancer cells. HT-29 
cells were treated with serial concentration of NBT, ATST, and their combinations for 72 
h. Viable cells were measure by cell viability assay as described in Material and methods. 
The half-dose combination produced much stronger growth inhibition on HT-29 cells 
than those caused by full-dose individual treatments of NBT and ATST. Data were 




Figure 5.2. Median effect (A) and interaction index plots (B) of NBT, ATST, and their 
combination in HCT human colon cancer cells. Cells were treated with NBT or ATST 
alone or in combination at serial concentrations for 72 h in 96-well plates. Cell viability 
was determined by MTT assay as described in Material and methods. The median effect 
plot and interaction index plot were constructed by using modified Chou and Talalay’s 
method as described in Materials and methods. Synergistic effect of two agents was 
defined as interaction index lower than 1.0. Error bars in interaction index plots 




5.3.2 NBT/ATST co-treatment synergistically induced G0/G1 cell cycle arrest and 
cellular apoptosis in human colon cancer cells 
To further investigate the molecular mechanism of NBT/ATST co-treatment in 
inhibiting the growth of colon cancer cells, we determined its effect on cell cycle and 
apoptosis by flow cytometric analysis. Out-of-control cell proliferation is one important 
characteristic of cancerous cells, thus induction of cell cycle arrest is a promising 
approach to regulate abnormal cell growth(25). As shown in Figure 5.3A, treatments with 
NBT (36 µM), ATST (18 µM) and their half dose co-treatment (NBT 18 µM + ATST 9 
µM) for 24 h resulted in cell cycle arrest at G0/G1 phase in HT-29 cells, and the effect of 
NBT/ATST co-treatment was stronger than those of NBT or ATST alone. NBT and 
ATST alone increased the accumulation of cell population in G0/G1 phase by 8.3 and 
12.7%, respectively, compared to the control cells. However, their half dose co-treatment 
increased that by 30.4%, compared to the control cells.  
Evasion of apoptosis, an essential form of programed cell death, is one of the 
most common hallmarks of cancer. Therefore, induction of apoptosis of cancer cells is 
another critical strategy for cancer prevention and treatment(25). To determine the pro-
apoptotic effects of NBT/ATST co-treatment, we performed annexin-V/propidium iodine 
double staining assay to evaluate the apoptosis of HT-29 cells, 48 h after treatment. As 
shown in Figure 5.3B, NBT at 36 µM did not caused significant change in the apoptotic 
cell population, in comparison to the control cells; while ATST at 18 µM significantly 
increased early and late apoptotic cell population by 2.5- and 2.6-fold, respectively. In 
contrast, the NBT/ATST co-treatment exerted a much stronger induction than that 
produced by ATST. The co-treatment resulted in 7.9- and 4.1-fold increase in early and 
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late apoptotic cell population compared to the control, respectively. Overall, NBT/ATST 
half dose combination treatment showed more potent effects in inducing G0/G1 cell cycle 
arrest and cellular apoptosis of HT-29 cells than NBT or ATST at full dose alone, 






Figure 5.3. Effects of NBT (36 µM), ATST (18 µM), and their half dose combination 
(NBT 18 µM + ATST 9 µM) on!cell cycle progression (A) and apoptosis (B) of HT-29 
human colon cancer cells. Cells were seeded in 6-well plates for 24 h, and then treated 
with NBT, ATST, and their half dose combination. After 24 or 48h of treatments,!cells 
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were harvested and subject to cell cycle and apoptosis analysis, respectively Data are 
shown as mean ± SD. Different notations in the bar charts indicate statistical significance 





5.3.3 Oral administration of NBT/ATST in combination decreased the incidence and 
multiplicity of colonic tumors in AOM-treated rats 
The AOM-induced colonic tumors share many histopathological characteristics 
with human colonic tumors, and has been used for more than four decades for assessing 
the chemopreventive of dietary agents on colon carcinogenesis. Injection of carcinogen 
AOM results in the development of colorectal dysplasia,!colonic aberrant crypt foci and 
cancer (122). Therefore, we utilized AOM-treated rat model to determine anti colon 
carcinogenic effects of dietary NBT, ATST and their half dose combination. Moreover, 
to mimic typical Western dietary composition, the rats were fed with a diet that contained 
20% fat. Body weight and food intake were monitored twice a week as important 
indicators of potential toxicity of NBT, ATST and their co-treatment. The results showed 
that no obvious difference was found among four groups during the whole experimental 
period (final body weights were shown in the Table 1). The weight of liver and spleen is 
important indicator of potential side-effects of dietary compounds. Significant increase in 
liver and/or spleen weight may be caused by general toxicity from dietary intake with 
NBT, ATST or their co-treatment. As shown in Table 1, there was no significant 
difference in the weight of liver and spleen among control, NBT and NBT/ATST co-
treatment groups, while ATST resulted in a slightly decrease in liver weight. And no 
apparent behavioral or appearance difference was observed either, suggesting no 
noticeable side effects caused by oral administration of NBT, ATST or their half dose 
combination. The ratio of colon weight/length reflects the severity of colitis, and thus is 
often considered as an important marker of inflammation in the colon in animal 
models(88). Our results suggested that although individual treatment with ATST had the 
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strongest reduction (18.4%) in the colon weight/length ratio, NBT/ATST co-treatment 
also significantly decreased that by 15.3% compared to the control rats, while individual 
treatment with NBT only showed a modest reduction (10.0%).  
Injection of AOM resulted in 80.0% tumor incidence and 1.86 ± 0.35 colonic 
tumors per rat. Dietary administration of 0.1% NBT significantly decreased tumor 
incidence to 66.7% and tumor multiplicity to 1.19 ± 0.21 tumors per rat; 0.04% ATST 
decreased tumor incidence to 60.0% and tumor multiplicity to 1.10 ± 0.23 tumors per rat. 
Whereas treatment with 0.05% NBT and 0.02% ATST exerted superior anti-tumor 
properties by reducing tumor incidence to 50.0% and tumor multiplicity to 0.62 ± 0.18 
tumors per rat. NBT/ATST at half dose combination led to a 37.5% reduction in tumor 
incidence and 66.7% in tumor multiplicity compared to the control rats. The enhanced 
chemopreventive effects (both tumor incidence and tumor multiplicity) by the 
combination treatment were confirmed to be synergistic by using the statistical analysis 




Table 5.1 Final body weight, relative organ weights, and colon assessment of rats 
 
Group! Control! NBT! ATST! NBT!+!ATST!!
Treatment( AOM( AOM/(0.1%(NBT( AOM/(0.04%(ATST( AOM/(0.05%(NBT/(0.02%(ATST(













684.73(±(15.98(a( 680.60(±(13.91(a( 657.09(±(10.41(a( 655.44(±(10.52(a(
Colon(length(
(mm)(













9.87(±(2.11(a( 8.88(±(1.59(abc( 8.05(±(1.73(c( 8.35(±(2.07(bc(
Tumor(incidence( 80.0(%(a( 66.7%(b( 60.0(%(c( 50.0(%(d(
Tumor(
multiplicity(
1.86(±(0.35(a( 1.19(±(0.21(b( 1.10(±(0.23(b( 0.62(±(0.18(c(
Data are shown as the mean ± SD. Different notation indicates statistical significance (p 





5.3.4 Oral administration of NBT/ATST reduced the levels of proinflammatory 
cytokines in the colon of AOM-treated rats 
Numerous studies have demonstrated that inflammatory bowel diseases (IBDs) in 
the colon, such as ulcerative colitis and Crohn’s disease could significantly increase the 
risk of colon cancer(78). Proinflammatory cytokines, such as!IL-1β, IL-6 and TNF-α play 
crucial roles in the pathogenesis of IBDs, where they regulate various aspects of 
inflammatory response(123). We previously reported that NBT showed significant 
inhibition on AOM/DSS-induced improper upregulation of IL-1β, IL-6 and TNF-α in 
mice(116). Therefore, we next evaluated the anti-inflammatory properties of NBT/ATST 
co-treatment in AOM-treated rats by real-time qRT-PCR analysis. As shown in Figure 
5.4, NBT, ATST and their co-treatment led to significant decreases in the mRNA levels 
of IL-1β by 84, 92 and 93% compared to the control group, respectively. For IL-6, NBT, 
ATST and their co-treatment reduced that by 66, 77 and 84%, respectively; for TNF-α, 
NBT, ATST and their co-treatment reduced that by 62, 79 and 85%, respectively. 
Together, our results clearly showed that NBT/ATST co-treatment had stronger 
inhibitory effects on inflammatory responses in the colon than that produced by NBT or 




Figure 5.4. Effects of NBT, ATST, and their half dose combination treatments on mRNA 
levels of IL-1β, IL-6, and TNF-α in the colonic mucosa of AOM-treated rats. Colon 
tissues samples were randomly collected from the middle and distal colon, and then 
subjected to qRT-PCR analysis. Data are shown as the mean ± SD of three independent 
experiments. The amount of IL-1β, IL-6, TNF-α mRNA expression was normalized to 
that of β-actin. Different notations in the bar charts indicate statistical significance (p < 





5.3.5 NBT/ATST modulated expression of key proteins related with cell cycle 
progression, apoptosis, angiogenesis and metastasis in AOM-treated rats 
To better understand the molecular mechanisms underlying the anti-carcinogenic 
activities of NBT/ATST co-treatment, we analyzed their effects on key signaling proteins 
related with cell cycle (p21, CDK2, CDK4, cyclin D and cyclin E), apoptosis (p53, 
cleaved caspase-7, cleaved caspase-3 and cleaved PARP), angiogenesis (VEGF) and 
metastasis (MMP-9) processes in AOM-treated rats by immunoblotting. As shown in 
Figure 5.5A, compared to the control group, all treatment groups significantly induced 
the expression levels of p21 and reduced the expression levels of CDK2, CDK4, cyclin D 
and cyclin E. However, ATST treatment showed the strongest effects on p21 and CDK4, 
whereas NBT/ATST co-treatment showed the strongest effects only on cyclin D, and 
similar degree of effects on CDK2 and cyclin E. The results suggested that ATST might 
contribute more than NBT for inducing cell cycle arrest.  
Immunoblotting analysis demonstrated that NBT/ATST co-treatment also 
extensive increased the expression levels of tumor suppressor p53, as well as cleavage of 
caspase-7, caspase-3 and PARP (Figure 5.5A). Moreover, the co-treatment resulted in 
dramatic decrease in the levels of VEGF and MMP-9 compared to the control group 
(Figure 5.5A). It is noteworthy that the co-treatment showed the strongest effects in 
modulating all these signaling proteins than NBT or ATST alone. Interestingly, NBT 
exerted more potent effects in the induction of pro-apoptotic biomarkers, while ATST 




5.3.6 NBT/ATST decreased the expression levels of p-EGFR, EGFR and RhoA in 
membrane-bound proteins  
Emerging evidence suggests that overexpression of Rho family of small G-
proteins, such as RhoA and RhoC is correlated with poor prognosis in certain kinds of 
cancers, including colon, breast, pancreas and bladder cancer. Previous studies have 
indicated that statins can suppress the geranylgeranylation of RhoA and in turn inhibit 
epidermal growth factor-induced invasion of cancer cells(66). Therefore, we next 
investigate the effects of NBT, ATST and their co-treatment on the expression levels of 
phosphorylated-EGFR (p-EGFR), EGFR and RhoA in membrane-bound proteins in 
AOM-treated rat colons. We isolated membrane fraction as previously described in 
Materials and methods. As shown in Figure 5.5B, NBT treatment modestly decreased the 
levels of p-EGFR and RhoA compared to the control, whereas ATST treatment 
significantly reduced the levels of p-EGFR, EGFR and RhoA. More importantly, their 
half dose combination markedly diminished the protein levels of p-EGFR, EGFR and 
RhoA, and its effects were much stronger than ATST alone. For example, for RhoA, 
NBT and ATST alone exhibited a 1.2- and 2.1-fold decrease, respectively, while the co-









Figure 5.5. (A) Effects of NBT, ATST, and their half dose combination treatments on 
cancer related signaling proteins in the colonic mucosa of AOM-treated rats. Colon 
tissues samples were randomly collected from the middle and distal colon, and then 
subjected to Western Blot analysis.!The numbers underneath of the blots represent band 
intensity (normalized to β-actin, means of three independent experiments) measured by 
Image J software. The SDs (all within ±15% of the means) were not shown. β-Actin was 
served as an equal loading control. * indicates statistical significance in comparison with 
the control (p < 0.05, n=3). (B) Effects of NBT, ATST, and their half dose combination 
treatments on membrane-bound proteins in the colonic mucosa of AOM-treated rats. 
Membrane-bound proteins were prepared as described in Material  and methods. The 
numbers underneath of the blots represent band intensity (normalized to β-actin, means of 
three independent experiments) measured by Image J software. The SDs (all within 
±15% of the means) were not shown. β-tubulin was served as an equal loading control. * 






In this study, for the first time, we revealed the potent synergistic 
chemopreventive effects of NBT and ATST in combination in human colon cancer cells, 
as well as AOM-induced colon carcinogenesis animal model. Using MTT cell viability 
assay, we found that NBT/ATST half dose combinations produced enhanced growth 
inhibitory effects on HT-29 human colon cancer cells. In addition, the isobologram 
analyses for the interactions between two agents comfirmed that the enhanced 
bioactivities of NBT/ATST in combination were synergistic. All NBT/ATST 
combination dose pairs resulted in interaction indexes lower than 1, and the interaction 
indexes of NBT/ATST at the two highest dosed pairs tested (12 µM NBT + 6 µM ATST, 
18 µM NBT + 9 µM ATST) were even lower than 0.3, suggesting a strong synergism. 
We further demonstrated that NBT/ATST half dose combination markedly arrested colon 
cancer cells in G0/G1 phase during cell cycle progression, and this effect was much 
stronger than those caused by NBT or ATST at full dose individually. Prolonged 
treatment with NBT/ATST greatly induced apoptosis of colon cancer cells that was more 
than two time stronger than that produced by individual ATST treatment, and could not 
be observed with individual NBT treatment. Our results showed that NBT and ATST had 
distinct activities on cell-cycle and apoptosis of HT-29 cells, suggesting that different 
molecular mechanisms were invloved in their mode of actions. A growing number of 
studies indicate that combination treatments of two or more chemopreventive agents that 
have distinct molecular targets may produce enhanced biological activities than those 
produced by each single agent alone(22). Therefore, the strong synergey between 
NBT/ATST co-treatment on cell proliferation of human colon cancer cells is of great 
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importance for its potential chemopreventive efficacy in further animal and human 
studies on colon cancer.  
 Our results from study in the AOM-induced colon carcinogenesis model indicated 
that the combination of NBT and ATST greatly inhibited the development of colon 
cancer in AOM-treated rats, which was evidenced by significantly decreased tumor 
incidence, tumor multiplicity, and weight/length ratio of colon by the co-treatment, in 
comparison to the AOM control group, as well as individual NBT or ATST treatment 
group. Based on the tumor incidence and tumor multiplicity results, statistical analysis 
confirmed the enhanced chemopreventive effects were synergistic. The dose of NBT used 
in the combination was based on the previous studies that showed NBT inhibited colon 
carcinogenesis in different rodent models(116). This dose is equivalent to approximately 
200 mg/person/day for human, which is a reasonably achievable dose in human. On the 
other hand, the dose of ATST used in the combination is equivalent to about 80 
mg/person/day for human, which is within the usual adult dose for cholesterol reduction 
and cardiovascular disease prevention (10 mg to 80 mg orally once a day). This is the 
first demonstration of the effectiveness of NBT/ATST combination in the inhibition of 
colon carcinogenesis in vivo, which may help lower the dose required for each compound 
in colon cancer chemoprevention in human.  
Patients with IBDs have an elevated risk of developing colitis-accociated colon 
cancer. The functional studies revealed that proinflammatory cytokines are invloved in 
experimental carcinogenesis. Blockade of IL-1β and TNF activity was shown to reduce 
tumor growth in rodent colon cancer models. Additionaly, suppression of IL-1β activity 
was found to inhibit colon carcinogenesis in mice by interfering macrophage-dependent 
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IL-6 secretion(123). We and other have demonstrated that NBT had potent anti-
inflammatory activities in clitis and colon cancer animal models by reducing the 
production of proinflammatory cytokines IL-1β, IL-6 and TNF-α, and downregualting 
inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) expression(15, 50, 
116). ATST is also reported to exert anti-inflammatory effects by modulating key 
inflammatory biomarkers, such as iNOS, COX-2, phospho-p65, IL-1β, IL-4 and TNF-α 
in AOM-treated rats(124). Our results indicated that NBT/ATST co-treatment had 
superior inhibitory effects on AOM-induced up-regulation of pro-inflammatory cytokines 
than individual treatment of NBT or ATST, suggesting that the chemopreventive effects 
of the co-treatment was assocaited its anti-inflammatory properties. 
Key signaling pathways related to cell cycle arrest and apoptosis are often 
deregulated during the promotion stage of carcinogenesis. Therefore, induction of cell 
cycle arrest and apoptosis are promising strategies for chemoprevention remedy. Cell 
cycle progression is precisely regulated by checkpoints and different cycline-cyclin-
dependent kinase (CDK) complexes. p21 is an important CDK inhibitor that mainly 
functions as a regulator of cycle cycle at G1 and S phase(25, 33). The activation of 
CDK4-cyclin D and CDK6-cyclin D complexes is essential for the transition from early 
to mid G1 phase, whereas the CDK2-cyclin E complex is necessary for the transition 
from mid G1 to S phase(125). Immunoblotting results from animal study further revealed 
that all treatment groups dramatically induced the expression levels of p21, although the 
NBT/ATST co-treatment exhibited a relatively less potent efficacy than individual NBT 
or ATST. And all treatment groups produced a similar degree of inhibition on protein 
levels of CDK2, CDK4 and cyclin E, whereas the co-treatment resulted in the strongest 
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inhibition on cyclin D. These findings are consistent with previous in vitro results on HT-
29 cells. In addition, in vitro results suggested that apoptosis contributed to the growth 
inhibitory effects of NBT/ATST co-treatment. In in vivo study, we found that the co-
treatment significantly increased the protein levels of tumor suppressor p53, cleaved 
caspase-7, cleaved caspase-3 and cleaved PARP. Cleavage of caspase-7 and its 
downstream effector caspase-3 play critical roles in triggering cellular apoptosis. 
Cleavage of caspase-3 can further cause the cleavage of PARP, which can ultimately lead 
to apoptosis by interfering chromatin condensation and DNA fragmentation(32).!
Interestingly, in HT-29 cells, we found that ATST might contribute more than NBT to the 
pro-apoptotic effects of the co-treatment. Immunoblotting results from animal study 
suggested that individual NBT treatment led to a stronger induction of apoptosis 
signaling proteins than individual ATST. This may be caused by the different ratio of 
NBT and ATST used in HT-29 cells and AOM-treated rats.   
Progression stage of carcinogenesis involves unlimited replication of tumor cells, 
activation of angiogenesis (new blood vessel formation), beginning of tissue invasion and 
metastasis growth(126).!Vascular endothelial growth factor (VEGF) is one of the major 
growth factors that is recruited and further activate endothelial cell functions. VEGF is 
often found to be overexpressed in many tumors(127).!Migration and invasion of tumor 
cells are important events during metastasis process of carcinogenesis. When solid 
tumors obtain adequate nutrient supply from new blood vessels, they will start to expand 
from the primary tumor mass into surrounding tissues. Additionally, tumor cells are able 
to travel through blood stream and migrate to secondary tissues. Proteolysis enzymes 
matrix metalloproteinases (MMPs) plays important roles in the disruption of extracellular 
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matrix. Among MMP family,!MMP-9 is a main proteolysis enzyme that breaks down 
extracellular matrix structure and thus opens paths for tumor cells migration(103, 128). 
Therefore, angiogenesis and metastasis process are important targets for 
chemoprevention. Our results clearly showed that NBT/ATST co-treatment drastically 
decreased the protein levels of VEGF and MMP-9, and these effects were either stronger 
than or similar to the individual treatment with NBT or ATST. These findings suggested 
that NBT/ATST co-treatment might be capable of suppressing the angiogenesis and 
metastasis process of colon cancer. 
Previous studies have demonstrated that the mechanism of action by which ATST 
inhibits cancer cell growth. Mevalonate, a major product of HMG-CoA reductase activity, 
is the precursor for some intermediate products such as farnesyl pyrophosphate and 
geranylgeranyl pyrophosphate, which further isoprenylate various small GTPase proteins 
including the Ras/Rho!superfamily. The isoprenylation is necessary for cytosol-to-
membrane translocation of these small GTPase proteins and thus become functional(67, 
68). Ras homolog gene family, member A (RhoA) is a major member of Ras/Rho!
superfamily that has been proven to be involved in cellular adhesion, migration, 
metastasis, proliferation and apoptosis of cancer cells (66, 69, 70).!In vitro study on 
HCT116 and HT-29 human colon cancer cell lines proposed that ATST modulated 
HMG-CoA reductase and geranylgeranylation of small G-protein, such as k-Ras and 
RhoA, as well as induced G0/G1 phase cell cycle arrest and apoptosis(71). Our results 
indicated that NBT/ATST co-treatment significantly diminished the protein levels of p-
EGFR, EGFR and RhoA, suggesting that the chemopreventive properties of the co-
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treatment could be at least partially attributed to its ability to inhibit EGFR 
phosphorylation and RhoA-mediated signaling pathways. 
 
In conclusion, our results demonstrated that treatments of NBT/ATST in 
combination exhibited a strong synergy in inhibiting HT-29 human colon cell growth, as 
well as causing cell cycle arrest and apoptosis. Furthermore, oral administration of NBT 
and ATST in combination synergistically inhibited colon carcinogenesis in AOM-treated 
rats. Real-time PCR and immunoblotting analysis suggested that NBT/ATST co-
treatment exerted chemopreventive effects via inhibiting AOM-stimulated up-regulation 
of proinflammatory cytokines, inducing cell cycle arrest and apoptosis, suppressing the 
protein levels of VEGF and MMP-9, and modulating the levels of membrane-bound 
protein RhoA, p-EGFR and EGFR. The strategy of using NBT and ATST in combination 
at a relatively low dose of each individual agent may help attenuate the potential toxicity 
of these two compounds. This study provided a scientific basis for utilizing NBT and 









At present, colon cancer is the fourth most commonly diagnosed cancer and the 
second leading cause of cancer death in the US among all types of cancer. Once the 
uncontrollable cells form to tumor, patients have to be treated with unwanted surgery, 
chemotherapy or other targeted therapies. Complications and serious side effects are 
associated with their long-term use. However, epidemiological evidences suggest that 
high consumption of fruits and vegetables is linked to around 20% lower risk of cancer 
occurrence. Chemoprevention by phytochemicals presented in fruits, vegetables and 
herbs have gained increasing attention in chemoprevention research. 
In this dissertation, the chemopreventive and anti-inflammatory properties of 
nobiletin (NBT) and its metabolites were demonstrated by using both cell culture studies 
and animal studies. Our results demonstrated that that oral intake of NBT effectively 
inhibited colitis-associated colon carcinogenesis in AOM/DSS-treated mice. We 
identified and quantified major metabolites of NBT in the colonic mucosa, and the 
abundance of these metabolites were about 20-fold higher than that of NBT in the colonic 
mucosa. Our results further demonstrated that colonic metabolites of NBT had stronger 
anticancer effects than NBT, which was evidenced by their superior effects in inhibiting 
cancer cell growth, inducing cell-cycle arrest and apoptosis, and modulating key 
signaling proteins. Together, our results showed that the chemopreventive effects of 
orally administered NBT against colon carcinogenesis were closely associated with its 
colonic metabolites. 4′-Demethylnobiletin (4DN) is a major metabolite of NBT, and its 
tissue level was found to be much higher than that of NBT after oral administration of 
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NBT in mice. We observed that 4DN, at physiologically achievable concentrations, 
effectively inhibited LPS-induced inflammation in macrophage cells through modulating 
NF-κB, AP-1 and Nrf2 signaling pathway. We also found that 4DN produced strong 
protective effects against TPA-induced skin inflammation in mouse ears. Together, our 
results suggested that 4DN had strong anti-inflammatory effects both in vitro and in vivo, 
providing a scientific basis for using NBT as a nutraceutical to prevent inflammation-
driven diseases in human. 
Accumulating studies have suggested that combination of cancer 
chemopreventive agents may produce enhanced protective effects against carcinogenesis 
than each individual agent alone. Our results indicated that treatment of NBT/ATST in 
combination exhibited strong synergy against colon cancer in both HT-29 human colon 
cancer cells and AOM-treated rats. NBT/ATST co-treatment at low doses produced much 
stronger chemopreventive effects on colon carcinogenesis than those produced by NBT 
or ATST alone at higher doses. And these enhanced activities were confirmed to be 
synergetic by statistic analyses. This study provided a rationale for combining NBT and 
ATST to prevent colon cancer in human. All in all, NBT and its metabolites exhibited 
promising chemopreventive effects that can be utilized to prevent and treat colitis and 
colon cancer in human in the future. The dissertation presented here provides important 
knowledge concerning the health promoting properties of PMFs and encourages future 
clinical studies.  
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